



US008008460B2

(12) **United States Patent**
Wolff et al.

(10) **Patent No.:** **US 8,008,460 B2**
(45) **Date of Patent:** ***Aug. 30, 2011**

(54) **POLYNUCLEOTIDE FRAGMENTS OF AN INFECTIOUS HUMAN ENDOGENOUS RETROVIRUS**

(75) Inventors: **Klaus Wolff**, Vienna (AT); **Hubert Pehamberger**, Vienna (AT); **Andreas Grassauer**, Vienna (AT); **Thomas Muster**, Vienna (AT)

(73) Assignee: **Avir Green Hills Biotechnology Research Development Trade AG**, Vienna (AT)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **12/261,374**

(22) Filed: **Oct. 30, 2008**

(65) **Prior Publication Data**

US 2009/0180975 A1 Jul. 16, 2009

Related U.S. Application Data

(63) Continuation of application No. 10/490,920, filed as application No. PCT/EP02/10899 on Sep. 27, 2002, now Pat. No. 7,510,862.

(30) **Foreign Application Priority Data**

Sep. 27, 2001 (AT) A 1539/2001

(51) **Int. Cl.**

C07H 21/02 (2006.01)

C07H 21/04 (2006.01)

C12N 15/00 (2006.01)

(52) **U.S. Cl.** **536/23.1; 536/24.3; 435/320.1**

(58) **Field of Classification Search** **536/23.1, 536/24.3; 435/320.1**

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,395,549	B1 *	5/2002	Tuan et al.	435/455
6,396,549	B1	5/2002	Weber	348/734
6,500,869	B1	12/2002	Driller et al.	514/931
7,256,274	B2	8/2007	Noteborn et al.	536/23.1

FOREIGN PATENT DOCUMENTS

DE	19811692	9/1999
JP	9252780	9/1997
WO	WO 98/24454	6/1998
WO	WO 99/67395	12/1999
WO	WO 00/06598	2/2000
WO	WO 00/20460	4/2000
WO	WO 00/53789	9/2000
WO	WO 01/62937	8/2001
WO	WO 01/70941	9/2001
WO	PCT/EP02/10899	* 4/2003

OTHER PUBLICATIONS

Balda et al., "Oncornavirus-like particles in human skin cancers," *Proc. Natl. Acad. Sci., USA*, 72(9):3697-3700, 1975.

Barbulescu et al., "A HERV-K provirus in chimpanzees, bonobos and gorillas, but not humans," *Current Biology*, 11(10):779-783, 2001.

Barbulescu et al., "Many human endogenous retrovirus K (HERV-K) proviruses are unique to humans," *Current Biology*, 9(4):861-868, 1999.

Bartlett et al., "Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults," *AIDS*, 15(11):1369-1377, 2001.

Birkmayer et al., "Oncorna-viral information in human melanoma," *Europe. J. Cancer*, 10:419-422, 1974.

Birkmayer et al., "Virus-like particles in metastases of human malignant melanoma," *Die Naturwissenschaften*, 59(8):36-370, 1972.

Burke, "Clearing the way for ribozymes," *Nature Biotechnology*, 15:414-415, 1997.

Ferko et al., "Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 nef-specific systemic and mucosal immune responses in mice," *J. Virol.*, 75(19):8899-8908, 2001.

GenBank Accession No. AF164614.

Komurian-Pradel et al., "Rapid communication molecular cloning and characterization of MSR-related sequences associated with retrovirus-like particles," *Virology*, 260(1):1-9, 1999.

Kuwabara et al., "Formation of a catalytically active dimer by trna val-driven short ribozymes," *Nature Biotechnology*, 16:961-965, 1998.

Löwer et al., "Identification of human endogenous retroviruses with complex mRNA expression and particle formation," *Proc. Natl. Acad. Sci., USA*, 90:4480-4484, 1993.

Löwer et al., "The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences," *Proc. Natl. Acad. Sci., USA*, 93(11):5177-5184, 1996.

Marimoutou et al., "Prognostic factors of combined viral load and CD4+ cell count responses under triple antiretroviral therapy, Aquitaine cohort," *J. Acquir. Immune Defic Syndr.*, 27(2):161-167, 1996-1998.

Muster et al., "An endogenous retrovirus derived from human melanoma cells," *Cancer Res.*, 63(24):8735-41, 2003.

Muster et al., "Detection of viral sequences and virus-like particles in human melanoma," *J. Invest. Dermatology*, 114(4):860, 2000.

Office Communication, dated Oct. 10, 2006.

Office Communication, dated Sep. 25, 2007.

Office Communication, dated May 29, 2008.

Pooga et al., "Cell penetrating DNA constructs regulate alanin receptor levels and modify transmission in vivo," *Nature Biotechnology*, 16:857-861, 1998.

Reus et al., "Genomic organization of the human endogenous retrovirus HERV-K(HML-2.HOM)(ERV-K6) on chromosome 7," *Genomics*, 72(3):314-320, 2001.

Reus et al., "HERV-K(OLD): ancestor sequences of the human endogenous retrovirus family HERV-K(HML-2)," *J. Virol.*, 75(19):8917-8926, 2001.

Turner et al., "Insertational polymorphisms of full-length endogenous retroviruses in humans," *Current Biology*, 11(19):1531-1535, 2001.

* cited by examiner

Primary Examiner — Wu-Cheng Winston Shen

(74) *Attorney, Agent, or Firm* — Fulbright & Jaworski LLP

(57) **ABSTRACT**

Nucleotide sequences and fragments which code for a human endogenous retrovirus which is infectious. "Fragments" according to the present invention relate also to specific fragments of the sequences inserted into the vector pCR4-Topo and deposited as MERV-env, MERV-gag, MERV-prt and MERV-pol as mentioned above. Additionally, methods of using such sequences, polypeptides encoded by such sequences, antibodies directed against such sequences, and methods and compositions relating to the same are all contemplated.

13 Claims, 11 Drawing Sheets

FIG. 1A

A




FIG. 1B

B




FIG. 2




FIG. 3





FIG. 4A






FIG. 4B






FIG. 5 a



b

FIG. 6







FIG. 7A-B

FIG. 8A

SEQ ID NO:48
 SEQ ID NO:49

```

        LacZα Initiations-Codon
        M13 Reverse priming-Stelle T3 priming-Stelle
        CACACAGGAA ACAGCTATGA CCATGATTAC GCCAAGCTCA GAATTAACCC TCACTAAAGG
        GTGTGTCCTT TGTCGATACT GGTACTAATG CCGTTCGAGT CTTAATTGGG AGTGATTTC

        SpeI Sse8387I (PstI) PmeI EcoRI EcoRI NotI
        261 GACTAGTCCT GCAGGTTTAA ACGAATTGCG CCTT PCR AAGGGC GAATTCGCGG
        CTGATCAGGA CGTCCAAATT TGCTTAAGCG GGA PCR Product TTCCCG CTTAAGCGCC

        T7 priming-Stelle M13 Forward (-20) priming-Stelle
        311 COGCTAAATT CAATTCGCC TATAGTGAGT CGTATTACAA TTCACTGGCC GTCGTTTTAC
        GCGATTMTAA GTAAGCGGG ATATCACTCA GCATAATGTT AAGTGACCGG CAGCAAATG
    
```




FIG. 8B

MERV gag

SEQ ID NO:50

...TTAAACGAATTCGCCCTTCTAGGGTGATAATGGGGCAAACATAAAAGTAAAATFAAAAGTAAATATGCCTCTTATCTC...

Vektor pCR4-TOPO Primer gag-Sequenz

...AAGCCAGTTACCACAATACAACAATTGTCCCCACCAAAAGCGGCAGTGCAGCAGTAGAAGGGCGAATCGCGGCCGCT...

gag-Sequenz Primer Vektor pCR4-TOPO

MERV prot

SEQ ID NO:51

...TTAAACGAATTCGCCCTTCAAGCGGCAGTGCAGCAGTAGATTTATGTACTATACAAGCAGTCTCTCTGCTTCCAGGG...

Vektor pCR4-TOPO Primer prot-Sequenz

...TTTTTACCATCCCTCTGGCGGAGCAGGATTGGGAAAAATTTGCCTTTACTATAC...GCAAGGGCGAATCGCGGCCGCT...

prot-Sequenz Primer Vektor pCR4-TOPO

MERV pol

SEQ ID NO:52

...TTAAACGAATTCGCCCTTGAAAAATTTGCCTTTACTATACCAGCCATAAATAATAAAGAACCAGCCACCAGGTTTCAG...

Vektor pCR4-TOPO Primer pol-Sequenz

...CTTCCTGTTTGGATACCCACTAGACATTTGAAGTTCTACAATGAACCCATCAGAGAGCAAGGGCGAATCGCGGCCGCT...

pol-Sequenz Primer Vektor pCR4-TOPO

MERV env

SEQ ID NO:53

...TTAAACGAATTCGCCCTTTACATGAACCCATCAGAGATGCAAAGAAAAGCACTCCGCGGAGACGGAGNACACCGCA...

Vektor pCR4-TOPO Primer env-Sequenz

...CAAGAGAGATCAGATTGTCACCTGTGTCTGTGTAGAAAAGAAGTAGACATAGGAGACTCCAAAGGGCGAATCGCGGCCGCT...

env-Sequenz Primer Vektor pCR4-TOPO

**POLYNUCLEOTIDE FRAGMENTS OF AN
INFECTIOUS HUMAN ENDOGENOUS
RETROVIRUS**

CROSS REFERENCE TO RELATED
APPLICATIONS

This application is a continuation of U.S. application Ser. No. 10/490,920 filed 26 Mar. 2004 now U.S. Pat. No. 7,510,862, which is a national phase application under 35 U.S.C. §371 of International Application No. PCT/EP02/10899 filed 27 Sep. 2002, which claims priority to Austrian Application No. A 1539/2001 filed 27 Sep. 2001, the contents of which are incorporated herein by reference in their entirety.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to human endogenous retroviruses, fragments thereof, a biologically functional vector comprising sequences of said retrovirus.

2. Description of Related Art

Endogenous retroviruses (ERVs) are integral parts in the genomes of many, if not of all, species. ERVs most probably, resulted from infection of germ line cells with exogenous retroviruses and subsequent fixation of their genetic information in the host genome.

Many types of human endogenous retroviruses (HERVs) have been characterized previously, and they have been classified into different groups, or families, partly on the basis of their sequence identity and partly according to the similarity of their primer binding sites (PBSs) to host tRNAs. Thus, members of the HERV.H family contain a PBS with a sequence similar to a region of tRNA^{His}, whereas the HERV.E family is primed by tRNA^{Glu}. Despite the large amount of data available, the classification of the many different HERV families within an overall phylogenetic framework has been hampered for several reasons: (i) some highly divergent retroviruses are primed by the same type of tRNA; (ii) many HERV families have not been fully characterized, and the sequence information that has been reported is often derived from different genomic regions, making interfamily comparisons problematic; and (iii) the relative lack of sequence information on other host taxa has made it difficult to distinguish between genuinely monophyletic HERV families and polyphyletic families that appear monophyletic only because similar viruses in other hosts have not yet been described. A pathogenic potential of nondefective endogenous retroviruses has so far only been demonstrated in mice, in which they may induce tumors and immunological disorders. In human DNA, endogenous retrovirus sequences (HERVs) are well known genetic elements. They all seem to be defective due to multiple termination codons, deletions, or the lack of a 5' long terminal repeat (LTR). Replication competent human endogenous retrovirus genomes have not yet been isolated.

Extensive studies on animal melanomas (especially that of the hamster), which serve as model for human malignant melanoma have shown the occurrence of virus particles in the tumors. A high molecular weight (70S) RNA species as well as an RNA-directed DNA polymerase, two diagnostic features for oncornavirus (oncogenic RNA) viruses have been associated with these particles. Cell-free transmission experiments end to the conclusion that hamster melanomas are caused by an RNA virus.

Based on these findings the working hypothesis was proposed that human melanoma may also have a viral etiology. In experiments the occurrence of virus-like particles as well as

reverse transcriptase activity in metastases of human melanoma was reported in the early 70s. (Birkmayer et al., *Europ. J. Cancer* 10 (1974) 419-422).

These virus-like particles are spherical or slightly ovoid and have a diameter of 90-120 nm. They have an electron-dense nucleoid measuring 50-70 nm across and are bounded by a triple-layered, 100 Å thick membrane. Sometimes fine projections extend radially from the nucleoid towards the membrane, and in this case the particles resemble those found in hamster melanoma. Their number is rather small in comparison to that found in hamster melanoma. So far, they have been seen only in the cytoplasm and no infectivity has been observed for these particles (Birkmayer et al., *Die Naturwissenschaften* 59 (8) (1972), 369-370).

Also Balda et al. (*Proc. Nat. Acad. Sci, USA* 72 (9) (1975, 3697-3700) described a high molecular weight RNA encapsulated with an RNA extracted DNA polymerase in particles possessing the identity characteristic of the RNA tumor viruses which was detected in human malignant melanomas. However, also here no infectious particles were observed.

Only many years later the expression of a family of human endogenous retrovirus sequences (HERV-K) in GH cells, a teratocarcinoma cell line producing the human teratocarcinoma-derived retrovirus (HTDV) particles was described (Löwer et al., *Proc. Natl. Acad. Sci. USA* 90 (1993): 4480-4484). Detailed electron microscopic surveys have revealed the existence of retrovirus-like particles in human placentas and teratocarcinoma cell lines. However, these found HERV-K/HTDV particles were also not infectious: They possess a distinct morphology: (i) they lack the electron lucent space normally seen between viral envelope and core, (ii) they seem to be predominantly arrested in budding stages, and (iii) collapsed cores, a consequence of a final proteolytic step in virus maturation, have never been observed. As long as the gag precursor remains uncleaved, resulting particles are not likely to be infectious.

A further HERV-K provirus was shown to be present in gorilla and chimpanzee genomes but not in the human genome (Barbulescu et al., *Current Biology* 11 (10) (2001), 779-783).

Therefore, human endogenous retroviruses have shown to be expressed, however, these virus particles found up to date were all non-infectious virus particles. Some endogenous retrovirus-like particles were found to be expressed in melanoma cells. However, the only infectious endogenous retroviruses found were some animal endogenous retroviruses, e.g. MelARV, a retrovirus capable of infecting cultured murine melanocytes which have also been shown to induce in some instances malignant transformation.

In the article by Reus et al. (*Journal of Virology*, October 2001, 8917-8926) it is stated that the average age of HERV-K proviruses is ca. 28 million years. It is described that at that time the HERV-Ks probably used to be infectious.

The WO 01/62937 A1 relates to retrovirus sequences and psoriasis.

In the WO 00/53789 A1 various retroviral expression vectors are listed.

The WO 00/20460 A1 relates to the detection of a HERV-K10 gag-sequence which is brought into relationship with the cancer seminoma, whereby the HERV-K10 gag-sequence is used as tumor marker as well as for therapeutic methods.

In the WO 00/06598 A1 a HERV-AVL3-B sequence fragment is brought in connection with methods for the treatment for malign melanomas.

The WO 99/67395 A1 relates to a 600 bp sequence of an env-gene of a virus family HERV-7q and relates to the use for or in connection with multiple sclerosis, and autoimmune diseases, respectively.

In the WO 98/24454 A1 the use of a retroviral ribozyme sequence HERV-PTN for the inhibition of tumor growth is described.

The JP 9252780 A relates to a method, in which a retrovirus polypeptide of the type HERV-E as a surrogate marker for cancer and other illnesses is detected.

The WO 01/70941 A2 relates to a retroviral sequence with high homology to the family HERV-H, whereby this sequence is brought into connection with multiple sclerosis.

The DE 198 11 692 A1 relates to a preparation for the protection against sun rays which is effective against herpes simplex viruses, whereby the preparation comprises organic and anorganic light filters.

SUMMARY OF THE INVENTION

The object of the present invention is therefore to provide at least a fragment of a nucleotide sequence which codes for a further human endogenous retrovirus which is infectious.

The object of the present invention is solved by a polynucleotide molecule being a fragment of a nucleotide sequence of an infectious human endogenous retrovirus which polynucleotide molecule comprises a sequence selected from the group consisting of

- (a) a sequence with at least 98%, preferably 99%, still preferred 99.5%, identity to a sequence according to SEQ ID No 1,
- (b) a sequence which hybridizes under stringent conditions with a nucleotide sequence according to said SEQ ID No 1,
- (c) a sequence which differs from said sequences (a) or (b) due to degeneration of the genetic code and
- (d) a sequence comprising sequences inserted into vectors pCR4-Topo and deposited as "MERV-env", "MERV-gag", "MERV-prt" and "MERV-pol" at the DSMZ on 26 Sep. 2001 or fragments thereof.

It has been surprisingly found that a polynucleotide molecule as mentioned above codes for (parts of) an infectious human endogenous retrovirus. With the present invention it can be shown for the first time that not only infectious animal endogenous retroviruses exist but also infectious human endogenous retroviruses. This is particularly surprising due to the fact that human endogenous retroviruses have been known and described for more than 30 years, however, even though many groups have been carrying out research in this field over decades, infectious human endogenous retroviruses could not be isolated or detected so far.

The polynucleotide molecule according to the present invention is preferably an isolated and a purified DNA or RNA molecule.

"Infectious" in the scope of the present application relates especially to retrovirus particles which are able to bind to the receptor of a cell over the env protein and enter into the cell and carry out a reverse transcription in order to produce a cDNA which can integrate into the host cell DNA. The differences between the life cycles of different retro elements and between infectious and non-infectious retroviruses is described in the article by Löwer et al. (*Proc. Natl. Acad. Sci* 93 (1996), 5177-5184), which is incorporated herein by reference.

Preferably, "infectious" human endogenous retroviruses according to the present invention are able to infect bovine MDBK cells and to integrate into these cells' genome.

The sequence according to SEQ ID NO 1 comprises a region which must be present in the polynucleotide molecule in order to code for an infectious human endogenous retrovirus (HERV). However, at both ends the polynucleotide molecule according to the present invention can comprise further herein not specifically described sequence regions, in particular LTR regions common to such viruses. With the present polynucleotide molecule any here not defined sequence regions can be identified by e.g. amplifying these sequences with the help of optimally designed gene specific primers which will for example bind to the above defined sequence regions. The amplification products can then be sequenced. Such methods are well known to the person skilled in the art.

"Stringent conditions" relate to hybridization reactions under defined hybridization conditions which is a function of factors as concentration of salt or formamide in the hybridization buffer, the temperature of the hybridization and the post-hybridization wash conditions. Such conditions for Northern Blot analysis are for example hybridization at 68° C. with a MERV-specific polynucleotide molecule labeled with dioxigenin or radioactive in a standard SSC hybridization buffer containing 0.1% SDS followed by stringent washing in wash buffer at the same temperature. Stringent washing can be performed for example by two times washing with 2× SSC buffer followed by two wash steps with 0.5× SSC buffer. In the present case stringent hybridization conditions will preferably involve a temperature of 15° C. to 25° C. below the melting temperature (T_m), whereby the T_m of a hybridization product of a nucleic acid probe can be calculated using a formula based on the g+c contained in the nucleic acids and that takes chain lengths into account, such as the formula $T_m = 81.5 + 16.6 (\log [Na^+]) + 0.41 (\% G+C) - 600/N$, wherein N=chain length (Sambrook et al. (1989), which is incorporated herein by reference). In practice an estimated T_m for an oligonucleotide probe is often confirmed and thus a person skilled in the art can calculate the T_m for any chosen probe whose nucleotide sequence is known.

Sequences which differ from a given sequence due to the degeneration of the genetic code can be defined by any person skilled in the art. This can be carried out electronically without undue burden.

In the scope of the present application the deposited vectors MERV-env, MERV-gag, MERV-prt and MERV-pol refer to plasmids deposited at the DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH) according to the Budapest Treaty and comprise the accession numbers DSM14540, DSM14538, DSM14536 and DSM14537.

In the scope of the present invention, when sequences inserted into the deposited vectors are concerned not only identical sequences are referred to but also sequences

- (a) with at least 98%, preferably 99%, still preferred 99.5%, identity to the sequences inserted into the deposited vectors,
- (b) which hybridize under stringent conditions with sequences inserted into the deposited vectors and
- (c) which differ from said sequences inserted into the deposited vectors due to degeneration of the genetic code.

The above polynucleotide molecule according to the present invention may further comprise a sequence which is at least 99.7%, 99.8% or 99.9% identical to SEQ ID NO 1.

Preferably, the polynucleotide molecule comprises a sequence according to SEQ ID NO 1 and is therefore identical to SEQ ID NO 1. This polynucleotide molecule has shown to code for a complete and active infectious particle of a HERV. The ORFs of SEQ ID NO 1 are preferably as follows:

ORF	Nucleotides	genetic code
gag	1-2013	universal
prt	1993-2809	nested reading frame
pol	3032-5650	universal
env	5352-7451	universal

Still preferred a polynucleotide molecule is provided which comprises a specific fragment of said above described polynucleotide molecule with a length of at least 15 bp, preferably at least 20 bp, still preferred at least 30 bp. The term "specific" defines any fragment which comprises a sequence different to any known HERV sequence. Therefore, any fragment with a length of at least 15 bp which comprises, for example, the in Table 1 mentioned mutations with respect to the known non-infectious HERV K (GeneBank, accession nr. 164614) will be comprised by the polynucleotide molecule according to the present invention. However, these given lengths are minimum lengths and also fragments which are longer, e.g. 100, 1000, 1500 bp, are also comprised by the term "fragment".

"Fragments" according to the present invention relate also to specific fragments of the sequences inserted into the vector pCR4-Topo and deposited as MERV-env, MERV-gag, MERV-prt and MERV-pol as mentioned above.

TABLE 1

clone name	position in MERV	position in HERV K108 (Accession 164614)	nucleotide change (MERV/HERV)	amino acid change (MERV/HERV)	
MERV gag	416	1515	C/T	Ala/Val	
	602	1701	C/A	Arg/Lys	
	630	1729	A/G	Pro/Pro	
	639	1738	T/C	Ala/Ala	
	654	1753	G/T	Pro/Pro	
	738	1837	G/A	Pro/Pro	
	799	1898	G/A	Glu/Lys	
	802	1901	C/T	Leu/leu	
	866	1965	T/C	Met/Thr	
	945	2044	A/G	Ser/Ser	
	953	2052	T/A	Met/Lys	
	972	2071	A/G	Glu/Glu	
	1149	2248	A/G	Gln/Arg	
	1348	2447	A/G	Lys/Gly	
	1413	2512	C/T	Ala/Ala	
	1642	2741	G/A	Gly/Arg	
	1653	2752	C/T	Tyr/Tyr	
	1668	2767	C/T	Ile/Ile	
	1701	2800	C/T	Asn/Asn	
	1989	3088	A/G	Pro/Pro	
	MERV prt	2068	3167	T/C	Ile/Thr
		2087	3186	C/A	Gly/Gly
		2090	3189	A/C	Pro/Pro
		2097	3196	G/A	Glu/Lys
		2100	3199	A/G	Arg/Gly
		2124	3223	A/C	Arg/Arg
		2163	3262	G/A	Gly/Ser
		2198	3297	G/A	Gln/Gln
		2238	3337	G/A	Gly/Arg
		2253	3352	G/C	Glu/Gln
		2273	3372	T/C	Tyr/Tyr
		2305	3404	C/T	Thr/Ile
		2313	3412	T/C	Phe/Leu
2330		3429	G/A	Pro/Pro	
2461		3560	G/A	Arg/Gln	
2501		3600	T/A	Gly/Gly	
2502		3601	T/C	Phe/Leu	
2543		3642	T/G	Thr/Thr	
2554		3653	G/A	Arg/His	
2590		3689	G/A	Arg/Gln	
2654		3753	A/G	Ala/Ala	

TABLE 1-continued

clone name	position in MERV	position in HERV K108 (Accession 164614)	nucleotide change (MERV/HERV)	amino acid change (MERV/HERV)
MERV prot	2659-2661	3758-3760	—/ATC	—/Ile
	2677	3776	T/C	Leu/Ser
	2741	3840	A/G	Gly/Gly
	2763	3862	G/A	Val/Ile
	2808	3907	T/A	Tyr/Asn
	2815	3914	T/G	Phe/Cys
	2816	3915	T/C	Phe/Cys
	2878	3977	G/A	Arg/Gln
	2938	4037	G/A	Arg/Gln
	2974	4073	A/G	His/Arg
	3052	4151	C/T	Ala/Ala
	3091	4190	T/C	Pro/Pro
	3105	4204	T/C	Leu/Pro
	3124	4223	C/T	Leu/Asp
	3178	4277	G/A	Ala/Ala
MERV pol	3363	4462	A/G	Tyr/Cys
	3664	4763	A/C	Ile/Ile
	3700	4799	A/G	Ile/Met
	4040	5139	C/A	Gln/Lys
	4115	5214	A/T	Met/Leu
	4219	5318	G/A	Gly/Gly
	4225	5324	G/A	Lys/Lys
	4255	5354	T/G	Ser/Ser
	4336	5435	C/A	Ala/Ala
	4465	5564	T/A	Thr/Thr
	4517	5616	G/C	Glu/Gln
	4771	5870	G/A	Ser/Ser
	4780	5879	T/C	His/His
	5402	6501	C/T	His/His
	MERV env	5719	6818	T/C
6456		7555	G/A	Val/Ile
6458		7557	C/T	Val/Ile
6464		7563	A/G	Leu/Leu
6802		7901	G/C	Gly/Ala
7146		8245	A/G	Lys/Glu
7262		8361	A/G	Thr/Thr
7340		8439	G/A	Arg/Arg
7347		8446	A/G	Asn/Asp
7388		8487	A/G	Ser/Ser
7436		8535	C/T	Val/Val

According to a preferred embodiment of the present invention a polynucleotide molecule encoding for an env protein of an infectious endogenous human retrovirus is provided, said polynucleotide molecule comprising a sequence selected from the group consisting of

(a) a sequence with at least 98%, preferably 99%, still preferred 99.5%, identity to a sequence according to SEQ ID No 2,

(b) a sequence which hybridizes under stringent conditions with a nucleotide sequence according to said SEQ ID No 2 and

(c) a sequence which differs from said sequence (a) or (b) due to degeneration of the genetic code.

"Env" according to the present invention relates also to the sequence inserted into the deposited MERV-env plasmid as mentioned above or a fragment thereof.

It is known that retroviruses are "quasispecies" and sequence variation in a given virus population is given. Such quasispecies variations are, of course, included in the definition of the present viruses and of the sequences of the nucleic acid molecules according to the present invention as long as the infectivity of the virus population as a whole is given.

"Env" relates to the envelope protein which is a viral membrane protein mediating the binding of the virus particles to the cellular receptors enabling virus entry which is the first step in a new replication cycle. The env protein is particularly important for the ability to spread between cells and individuals (infectivity).

A further embodiment of the present invention relates to a polynucleotide molecule encoding for a pol protein of a HERV, whereby said polynucleotide molecule comprises a sequence selected from the group consisting of

- (a) a sequence with at least 99%, preferably 99.5%, still preferred 99.8%, identity to a sequence according to SEQ ID No 3,
- (b) a sequence which hybridizes under stringent conditions with a nucleotide sequence according to said SEQ ID No 3 and
- (c) a sequence which differs from said sequence (a) or (b) due to degeneration of the genetic code. "pol" relates to the polymerase which is an enzyme with RNA dependant reverse transcriptase activity. Also this protein is important for a correct viral replication cycle.

"Pol" according to the present invention relates also to the sequence inserted into the deposited MERV-pol plasmid as mentioned above or a fragment thereof.

A still further aspect of the present invention relates to a polynucleotide molecule encoding for a gag protein of a HERV, whereby said polynucleotide molecule comprises a sequence selected from the group consisting of

- (a) a sequence with at least 98%, preferably 99%, still preferred 99.5%, identity to a sequence according to SEQ ID No 4,
- (b) a sequence which hybridizes under stringent conditions with a nucleotide sequence according to said SEQ ID No 4 and
- (c) a sequence which differs from said sequence (a) or (b) due to degeneration of the genetic code.

The gag gene products have acquired the ability to be transported to the cell surface and abut on the cell membrane incorporating env proteins during this process. The gag gene codes for a long polyprotein which in a first step is cut from the long molecule chain and is then cut into a number of parts which are present around the RNA in form of capsomeres. Since these gag proteins are essential for the budding they are important for the infectious viral circle.

"Gag" according to the present invention relates also to the sequence inserted into the deposited MERV-gag plasmid as mentioned above or a fragment thereof.

A further embodiment relates to a polynucleotide molecule encoding for a pro protein of a HERV, whereby said polynucleotide molecule comprises a sequence selected from the group consisting of

- (a) a sequence with at least 98%, preferably 99%, still preferred 99.5%, identity to a sequence according to SEQ ID No 5,
- (b) a sequence which hybridizes under stringent conditions with a nucleotide sequence according to said SEQ ID No 5 and
- (c) a sequence which differs from said sequence (a) or (b) due to degeneration of the genetic code.

The pro gene comprises 3 regions of particular interest:

1. dUTPase, dUTPase hydrolyses dUTP to dUMP and pyrophosphate.
2. prt retroviral Aspartyl-Proteinase
3. G_patch, α -glycine rich nucleic binding domain; A predicted glycine rich nucleic binding domain found in the splicing factor 45, SON DNA binding protein and D-type Retrovirus-polyproteins.

"Pro" according to the present invention relates also to the sequence inserted into the deposited MERV-prt plasmid as mentioned above or a fragment thereof.

Advantageously, a polynucleotide molecule is provided which comprises a sequence which is complementary to one of the above mentioned sequences according to the present

invention. Therefore, not only the sequence according to the RNA strand present in the retrovirus particle is provided but also a sequence according to the cDNA sequence.

Still preferred, the polynucleotide molecule comprises a detectable label. In particular if the polynucleotide molecule is a fragment of the above defined sequence, the polynucleotide molecule can be used for the detection of infectious HERV in a sample. The term "detectable label" relates to any marker well known in the art, e.g. fluorescent, radioactive, enzymatic or chemical marker.

A further aspect of the present invention relates to a polynucleotide molecule coding for a ribozyme, which comprises two sections, each of which has a length of at least 10 to 15 base pairs and which are complementary to specific sequence sections of said above identified polynucleotide molecule according to the present invention so that said ribozyme complexes and cuts the mRNA transcribed by a natural infectious human endogenous retrovirus DNA. The publication by John M. Burg "Clearing the Way for Ribozymes" (Nat. Biotechnology 15:414-415 (1997)) relates to the general mode of function of ribozymes and is included herein by reference. The ribozyme will recognize the mRNA of infectious HERV by complementary base pairing with said mRNA. The ribozyme will then cleave and destroy the RNA in a sequence specific manner before the HERV is translated. After dissociation from the cleaved substrate the ribozyme will repeatedly hybridize with specific RNA molecules and act as specific endonuclease. In general, ribozymes may specifically be produced for inactivation of a certain mRNA even if not the entire DNA sequence which codes for the infectious HERV is known.

Ribozymes are particularly efficient if the ribosomes move slowly along the mRNA. In that case it is easier for the ribozyme to find a ribosome free site on the mRNA. For this slow ribosomes mutants are also suitable as a system for ribozymes (J. Jayburg (1997), Nature Biotechnology 414-415). A further possible way is also to use a varied form of a ribozyme, i.e. a minizyme. Minizymes are efficient particularly for cleaving larger mRNA molecules. A minizyme is a hammer head ribozyme which has a short oligonucleotide linker instead of the stem/loop II. Primer minizymes are particularly efficient (Kufner et al. (1998), Nature Biotechnology 16, 961-965).

Here again the ribozyme comprises sequence sections which are complementary to "specific" sequence sections of the above defined polynucleotide molecule according to the present invention. It is sufficient if at least one of the two sequence sections is specific, meaning that this specific sequence section will only bind to an infectious HERV according to the present invention and not to already known and described non-infectious HERV sequences. Preferably, however, both sequence sections are specific for the above defined polynucleotide molecule according to the present invention, meaning that both sequence sections bind only infectious HERV sequences.

A further aspect of the present invention refers to a primer pair whereby the primers specifically hybridize to a polynucleotide molecule according to the present invention for an amplification reaction of a fragment of said polynucleotide molecule.

Here again the term "specifically" refers to primers which will only bind to the above defined polynucleotide molecule according to the present invention and not to any known already described HERV. It is sufficient, if only one of the primers is specific for the inventive polynucleotide molecule, however, preferably both primers bind specifically only to the inventive HERV polynucleotide molecule. This primer pair

can be used for any detection reaction in order to detect the presence of a HERV in a sample, whereby the term “amplification reaction” relates to any reaction specifically amplifying a sequence corresponding to the above described HERV sequence according to the present invention. This may be, for example, a conventional PCR as well as RT-PCR which are both well known to a person skilled in the art. However, the primer pair can also be used to find further herein not defined parts of the infectious HERV provirus according to the present invention. The primer pair can furthermore be used to identify other infectious HERVs which comprise, at least partly, similar sequences to the sequence of the infectious HERV according to the present invention.

The skilled man in the art easily finds conditions wherein primers which are specific for the infectious HERV sequences according to the present invention (which e.g. differ from sequences of known (non-infectious) HERVs by only 1, 2 or 3 nucleotides) only hybridize or anneal to the sequences of the infectious HERVs according to the present invention, but not to e.g. the non-infectious HERV sequences known. Examples for such specific regions are e.g. the regions covering one or more of the mutations listed in Table 1. Further examples may be derived by the skilled man in the art e.g. by comparing the sequences of the present infectious HERV with the known (non-infectious) HERV-K sequences (e.g. HERV-K108).

A further aspect of the present invention relates to a biologically functional vector comprising a polynucleotide molecule according to the present invention. The biologically functional vector will comprise all elements necessary for efficiently expressing the polynucleotide molecule according to the present invention whereby these elements, e.g. the promoter will be selected according to the host into which the functional vector will be transfected and in which the polynucleotide molecule will be expressed, e.g. to produce a protein or polypeptide encoded by the present infectious HERV sequences. A person skilled in the art can select the optimal biologically functional vector without undue burden.

Still preferred, a biologically functional vector comprising a polynucleotide molecule as defined above according to the present invention in inverse orientation with respect to the promoter is provided. This vector allows the production of antisense mRNA which is complementary to the mRNA of the infectious HERV according to the present invention. The antisense mRNA will bind to the respective region of the infectious HERV mRNA and therefore block any further translation and production of viral proteins and therefore infectious viral particles. Hereby it is sufficient, if an essential part of the infectious HERV mRNA is blocked in order to block the production of a complete infectious viral particle, e.g. part of the gag, pol, pro or env mRNA. Therefore, said biologically functional vector can be used in cell cultures to stop the viral production as well as a gene therapy against or prevention of viral replication in a patient.

A further aspect of the present invention relates to a recombinant host cell stably transfected with said biologically functional vector according to the present invention as defined above. Here, the person skilled in the art will select the vector and host cell in order to achieve an effective result, e.g. high expression of the infectious HERV or fragments thereof. Transfection methods in order to produce a recombinant host cell are well known to the person skilled in the art and may comprise any electroporation, lipofectamin transfection, salt transfection etc. Depending on the vector which is transfected into the host cell, the host cell will either express viral peptides, proteins or particles or produce antisense mRNA.

Still preferred the host cell is a mammalian cell. This will allow the production of infectious HERV proteins or peptides

with correct post-translational modifications. The mammalian cell may be, for example, from any human cell line.

A further aspect of the present invention relates to a method for producing an infectious human endogenous retrovirus or at least one fragment thereof comprising the steps of

- (a) transfecting a host cell with a vector as defined above according to the present invention,
- (b) selecting and cultivating cells which are stably transfected with said vector and
- (c) isolating and purifying said retrovirus or said fragment.

Here again the above mentioned definitions and preferred embodiments apply, in particular with respect to the transfection step and the selection of the host cell and vector. The selection of stably transfected cells may be carried out according to any method well known in the art, e.g. selection with antibiotic resistance or optical selection. The term “fragment” relates to any peptide encoded by the above defined polynucleotide molecule according to the present invention. However, the fragment will preferably refer to a peptide which can be used as an antigen. To detect fragments which can be used as antigens known homologous fragments of corresponding HERVs or ERVs can be used, however, such fragments can also be detected by providing a sample of antibodies of infectious HERV, which sample can be taken of an infected patient, incubating said antibody or antibodies with one or more fragments of the infectious HERV proteins in conditions so that a binding between corresponding antigens and antibodies occur and identifying the respective fragments which have bound to antibodies of infectious HERV.

A further aspect of the present invention relates to an infectious human endogenous retrovirus comprising as RNA a polynucleotide molecule according to the present invention. Preferably the infectious HERV according to the present invention will comprise the complete polynucleotide molecule, e.g. comprising the pol, env, gag, pro genes as well as LTR sequences. However, it is also possible that the RNA comprises only one or a few, but not all of the above mentioned genes. It is important that the HERV is able to carry out a complete retroviral replication cycle and infect further cells.

Furthermore, an infectious human endogenous retrovirus is provided being encoded by a polynucleotide molecule as defined above according to the present invention.

A further aspect of the present invention relates to a preparation comprising an infectious HERV according to the present invention. The preparation may be a pharmaceutical preparation in which case preferably a pharmaceutically acceptable carrier is provided. However, the preparation may also be designed for diagnostic purposes as well as analytical or other purposes, e.g. to produce antibodies, to study the effects in animals etc. Of course, the preparation according to the present invention will comprise any additional substances depending on the use of the preparation. The preparation may comprise further virus particles, as non-infectious HERVs. However, at least one infectious HERV according to the present invention or a significant portion of the preparation leading to the overall infectivity of this preparation must be present.

A further aspect of the present invention relates to an env protein, a pol protein, a gag, a pro protein encoded by a polynucleotide molecule as defined above according to the present invention. These proteins can be used for any analytical, diagnostic or production methods and they will be provided in any form, e.g. with additional substances, depending on the use of the protein.

Furthermore a peptide is provided which is a specific fragment of said retrovirus as defined above according to the present invention. Here again, “specific” refers to any frag-

11

ment which is not identical to a non-infectious HERV fragment already known. As mentioned above already the fragment may be any fragment of said retrovirus particle, however, preferably said fragment can be used as an antigen (e.g. a T or B cell epitope) and therefore be used in diagnostic methods as well as for the induction of the production of respective antibodies in a patient or animal and/or for the induction of specific T cell responses, both TH1 and TH2. The detection of such fragments can be carried out as described above.

The following fragments are examples of such antigens: Fragments of the gag protein may be:

LMQNEAIEQVRAICL,	(SEQ ID NO: 9)
IPYDWEILAKSSLSLSP,	(SEQ ID NO: 10)
ADQLLGIGQNWSTIS,	(SEQ ID NO: 11)
TISQQALMQNEAIEQ,	(SEQ ID NO: 12)
EKARKVIVELMAYEN,	(SEQ ID NO: 13)
MAYENANPECQSAIK,	(SEQ ID NO: 14)
PVLNKQNIITIQATTT,	(SEQ ID NO: 15)
RSKFDKNGQPLSGNE,	(SEQ ID NO: 16)
LSGNEQRGQPQAPQQ,	(SEQ ID NO: 17)
QPPLSQVFQGISQLP,	(SEQ ID NO: 18)
EIIDKSRKEGDTEAW,	(SEQ ID NO: 19)
VSTKNLIKL,	(SEQ ID NO: 20)
GIGQNWSTI,	(SEQ ID NO: 21)
QYGPNSPYM,	(SEQ ID NO: 22)
CPVLNKQNI,	(SEQ ID NO: 23)
LTVWNDWAI,	(SEQ ID NO: 24)
KFDKNGQPL,	(SEQ ID NO: 25)
GKCYNCGQI,	(SEQ ID NO: 26)
HLKKNCPVL,	(SEQ ID NO: 27)
GRKGNIIPL,	(SEQ ID NO: 28)
FSIKMLKDM	(SEQ ID NO: 29)

Fragments of the env protein may be:

PAVSDSLTESLTKHK,	(SEQ ID NO: 30)
WNSQSSIDQKLANQI,	(SEQ ID NO: 31)
VSMRDPWEASPSVHI,	(SEQ ID NO: 32)
PAVQNWLVVPTVSP,	(SEQ ID NO: 33)
LRPRVNYLQDFSYQR,	(SEQ ID NO: 34)
NTEVLVWEECVANSA,	(SEQ ID NO: 35)
SAVILQNNFEGTIID,	(SEQ ID NO: 36)
QFYHNCSGQTQSCPS,	(SEQ ID NO: 37)
NRSKRFIPTLIIVIM,	(SEQ ID NO: 38)
PYMLVVGNI,	(SEQ ID NO: 39)

12

-continued

IFKASKAHL,	(SEQ ID NO: 40)
KTIGSTTII,	(SEQ ID NO: 41)
GYHYPPICL,	(SEQ ID NO: 42)
SYQRSLKFR,	(SEQ ID NO: 43)
KGKPCPKEI,	(SEQ ID NO: 44)
VEVPTVSPV,	(SEQ ID NO: 45)
SLRPRVNYL,	(SEQ ID NO: 46)
TFNWQHRIL	(SEQ ID NO: 47)

15 Preferably, such peptide fragments contain at least 6 amino acid residues with at least one residue being specific for the present infectious HERV sequences, especially at least one of the amino acid residues not being present in the (non-infectious) HERV-K (HERV-K108). More preferred these peptides have a length from 7 to 15 amino acids, especially from 8 to 20 11. Such peptide fragments of these lengths are preferably fragments of the above mentioned gag and env fragments.

A further aspect of the present invention relates to an antibody which is directed against an antigen derived from said retrovirus as defined above according to the present invention. The production of antibodies towards any specific antigen may be carried out according to any method well known in the state of the art, e.g. by immunization of an animal and producing the antibodies in cell culture. The term "antibody" 25 refers to any form of antibody, e.g. monoclonal, polyclonal, humanized antibody etc. The antibodies directed against antigens from the infectious HERV according to the present invention can be used in immunizing methods, diagnostic methods or therapeutic methods. 35

Preferably, an antibody fragment is provided which is directed against an antigen derived from said retrovirus as defined above according to the present invention. Such antibody fragments may be for example Fa, F(ab)² or Fv which are capable of binding an epitopic determinant. Furthermore, single chain antibodies are comprised by the term "antibody fragment". These antibody fragments can be used as described above for the antibodies, however, due to their smaller size they may show advantages with respect to stability, production etc. Also here, the antibody fragment is specific, meaning that the antibody fragment comprises a sequence specific to infectious HERV according to the present invention. 40

A further aspect of the present invention relates to a solid support which has attached to its surface said antibodies defined above according to the present invention or said antibody fragments as defined above according to the present invention. The solid support according to the present invention may be of any size or shape, e.g. in the form of a flat slide, microtiter plate, chip, filter, column, membrane etc. and may 55 be made of any material generally used for solid supports, e.g. modified or unmodified glass, polymeric material etc. Hereby the antibody or antibody fragment can be attached to the complete surface of the solid support. However, it may also be attached in localized regions, as for example spots. Also the quantity in which the antibody is bound to said solid support may vary according to the size of the antibody or antibody fragment. Of course, for high throughput assays it will be advantageous to use micro array chips on which the antibodies or antibody fragments are bound in high density. The selection of the solid support and the mode of attachment of the antibody to its surface will depend on the use of said solid 65

support, e.g. for preparation, purification methods, detection methods, etc. and a person skilled in the art will be able to select the most appropriate solid support and the optimum mode of attachment of said antibody or antibody fragment to said solid support.

A further aspect of the present invention relates to a method for diagnosing cancerous cells comprising the steps of

- (a) providing a sample of said cells to be tested or supernatant thereof,
- (b) analyzing whether or not said infectious endogenous retrovirus according to the present invention as described above or fragment thereof is present in said sample whereby
- (c) the presence of said retrovirus or fragment thereof in said sample diagnoses cancerous cells.

The term “cancerous cells” refers to malignant tumor cells. It has been surprisingly found that the infectious HERV according to the present invention is related to the transformation of cells into cancerous cells, especially melanomas. Therefore, by detecting the presence of said infectious HERV it is possible to diagnose cancerous cells already at a very early stage. Therefore, the term “diagnosing cancerous cells” includes also diagnosing cells which will be transformed into cancerous cells, however, with conventional methods these cells would not yet be diagnosed as transformed.

However, it is not necessary to detect the complete infectious endogenous retrovirus. It is sufficient to detect at least one specific fragment thereof. Here again, the term “specific” refers to a fragment containing a sequence which differs from the sequences of the known non-infectious HERVs. The detection method may be carried out according to any protocol known in the art whereby it is possible to detect said infectious HERV or fragment thereof on DNA, RNA or protein level. It is further possible to determine the stage of cancer by determining the amount of infectious HERV.

Preferably, said analyzing step comprises an antigen-antibody reaction using an antibody or antibody fragment as defined above according to the present invention in order to detect proteins or protein fragments of said retrovirus. Here, any known antigen-antibody reaction may be carried out, e.g. on solid support, in liquid phase, by sandwich-ELISA, etc. It is, of course, possible to detect antibodies in said sample, however, since the production of antibodies may vary, it is preferred to detect an antigen in said sample by providing one or more specific antibodies whereby these antibodies may be bound to a solid support and/or comprise a label which may be detected and quantified.

According to a preferred method said analyzing step comprises detecting the polynucleotide sequence of said retrovirus and a fragment of the polynucleotide sequence specific for said retrovirus, respectively, whereby a hybridization reaction or amplification reaction is carried out using a polynucleotide as defined above according to the present invention. Hereby, the term “polynucleotide sequence” comprises RNA sequences, e.g. the polynucleotide molecule derived from the transcription of the respective DNA or the polynucleotide molecule present in the virus particle, as well as DNA, e.g. cDNA resulting from the reverse transcriptase reaction thereafter, whereby the cDNA may be still present in the virus particle or also the DNA already integrated into the host DNA. Therefore, said amplification reaction will comprise PCR as well as RT-PCR. Therefore, the above mentioned primer pair will preferably be used.

Advantageously, said polynucleotide sequence is transformed into cDNA in a reverse transcription step prior to said hybridization step and amplification reaction, respectively. Said hybridization step will be preferably carried out with one

of the above defined fragments of said polynucleotide molecule according to the present invention as mentioned above. Hereby it is, of course, possible to use labeled fragments or labeled nucleotides, e.g. retroactive nucleotides in order to easily detect and quantify, respectively, said polynucleotide sequence.

According to a further preferred method said analyzing step comprises

- (a) providing cells devoid of said endogenous retrovirus,
- (b) adding said supernatant of said sample to said cells,
- (c) cultivating said cells and
- (d) detecting a polynucleotide molecule as defined above according to the present invention in the DNA of said cells.

Since the HERV according to the present invention is infectious, the supernatant of said sample—if it comprises an infectious HERV—will infect the cells devoid of said endogenous retrovirus. After infection the infectious HERVs will integrate into said cells and further HERV particles will be produced. After cultivating said cells, therefore, the integrated polynucleotide molecule of the infectious HERV as defined above will be detectable in the DNA of said cells. This is a very reliable and quick method for detecting infectious HERVs. Again, the detection of said polynucleotide molecule may be carried out by a hybridization step and amplification reaction, respectively.

Preferably said cells are non-human cells. Since non-human cells do not comprise HERVs, the detection of a HERV polynucleotide molecule in said human cells will be a clear method of detecting infectious HERV particles. Preferably, said non-human cells are bovine cells. Infectivity of the virus particles with respect to these non-human cells is also a way of defining infectivity according to the present invention.

Still preferred said sample is a skin tissue sample from a patient. Since said infectious HERVs preferably infect skin tissue cells, a sample of a skin tissue is preferably used in order to detect said infectious HERVs.

Still preferred, said sample comprises melanocytes. Since said infectious HERVs are related to cancerous cells a sample comprising melanocytes is a preferred sample for detecting infectious HERVs according to the present invention.

According to a preferred embodiment of the present invention a method is provided for diagnosing cancer in a patient comprising the steps of

- (a) providing a sample of said patient to be tested,
- (b) analyzing whether or not at least one antibody as defined above or antibody fragment as defined above according to the present invention is present in said sample whereby
- (c) the presence of said antibody or fragment thereof in said sample diagnoses cancer.

Here again, the same definitions and preferred embodiments as mentioned above apply.

Preferably said sample is a blood sample of said patient. A blood sample is very easily and quickly taken from a patient without necessity of costly apparatuses. Furthermore, it is possible to diagnose an unlimited amount of samples in a very short time. As mentioned above for high throughput assays it is preferable to use microarrays.

According to an advantageous method said analyzing step comprises an antigen-antibody reaction using an antigen derived from said retrovirus as defined above according to the present invention. Here again, the above mentioned definitions and preferred embodiments apply.

According to a further advantageous embodiment a kit is provided for diagnosing cancerous cells according to the method as mentioned above according to the present invention comprising

- (a) a first reagent comprising a polynucleotide molecule as defined above according to the present invention, an antibody as defined above according to the present invention or an antibody fragment as defined above according to the present invention or a solid support as defined above according to the present invention and
- (b) as a positive control a second reagent comprising a polynucleotide comprising a sequence which is complementary to the sequence of said polynucleotide in said first reagent or a retrovirus as defined above according to the present invention, an env protein as defined above according to the present invention, a pol protein as defined above, a gag protein as defined above or a peptide as defined above according to the present invention. Here again, the same definitions and preferred embodiments as described above apply. Of course, it is also possible to provide additionally to the first reagent a further solid support without attached antibodies or antibody fragments. In this case the antibody or antibody fragment as well as the mode of attachment can be varied.

According to a further embodiment of the present invention a kit for carrying out a method for diagnosing cancer in a patient as described above is provided comprising

- (a) a first reagent comprising an antigen derived from said retrovirus as defined above and
- (b) as a positive control a second reagent comprising an antibody according to the present invention or an antibody fragment as defined above specific for said antigen in said first reagent.

Here again the same definitions and preferred embodiments as described above apply.

Preferably, said antigen is labeled with a detectable marker. This marker may be for example radioactive, fluorescent, an enzymatically or chemically detectable marker.

Such markers are well known in the state of the art and the person skilled in the art will be able to select the optimal marker.

Still preferred, said antigen is immobilized to a solid support. This allows an easy handling of said kit and the method can be carried out immediately without prior preparations.

According to a further embodiment of the present invention a PNA molecule is provided which comprises a base sequence complementary to the sequence of said polynucleotide molecule as defined above according to the present invention. PNA (peptide nucleic acid) is a DNA like sequence, the nucleic basis being bound to a pseudo peptide backbone. PNA generally hybridizes with complementary DNA, RNA or DNA polymers by Watson-Creek base pair and helix formation. The peptide backbone ensures a greater resistance to enzymatic degradation. The PNA molecule thus is an improved antisense agent.

Here, the advantage lies in that neither nucleases nor proteases are capable of attacking a PNA molecule. Therefore, the PNA molecule is highly stable, if it is bound to a complementary sequence, since it comprises a sufficient steric blocking of DNA and RNA polymerases, reverse transcriptase, telomerase and ribosomes (Buga et al, "Cell Penetrating DNA Constructs Regulate Alanin Receptor Levels and Modify Transmission in vivo", Nature Biotechnology 16:857-861 (1998)).

As in the case of the antisense RNA, if the PNA molecule comprises the above defined sequence it will bind to the

DNA/RNA or to a site of the DNA/RNA respectively, which codes for infectious HERV peptides. In this way, the PNA molecule will inhibit the transcription of the virus. The PNA molecule is prepared synthetically, e.g. by aid of the T-boc technique, since it is neither transcribed nor translated.

The present invention also relates to the use of anti-retroviral substances for preparing a medicament to treat melanoma. The present invention therefore provides a method for treating patients having or being at risk of developing melanoma comprising administering an effective amount of substances acting against retroviruses, e.g. substances which inhibit replication and polymerization of retroviral (infectious HERV) genomes. Examples of such treatment are e.g. known for the treatment of HIV infections.

Preferably, a pharmaceutical composition is provided comprising a polynucleotide as defined above according to the present invention, a vector as defined above according to the present invention, an antibody as defined above, an antibody fragment as defined above and a PNA molecule as defined above, respectively, and a pharmaceutically acceptable carrier. Of course, the pharmaceutical composition may comprise any further molecules or substances useful for a therapeutic method. The pharmaceutical composition may for example be provided as a skin cream or lotion, which may for example be used as an after sun lotion in a preventive manner.

Preferably, the pharmaceutical composition further comprises at least one antiviral substance, especially anti-retroviral substances. These may be any substances well known in the art, for example the agents used in known triple anti-retroviral therapy, see for example Bartlett J A, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS. 2001 Jul. 27; 15(11):1369-77; Marimoutou C, Chene G, Mercie P, Neau D, Farbos S, Morlat P, Ceccaldi J, Dabis F. Prognostic factors of combined viral load and CD4+ cell count responses under triple antiretroviral therapy, Aquitaine cohort, 1996-1998. J Acquir Immune Defic Syndr. 2001 Jun. 1; 27(2):161-7, which are incorporated herein by reference.

According to a further embodiment of the present invention a sun cream is provided which comprises a polynucleotide as defined above according to the present invention, an antibody, an antibody fragment as defined above and a PNA molecule as defined above, respectively, and at least one UV-protection substance. Therefore, applying a sun cream with these substances will prevent or inhibit the production of or infection by infectious HERV according to the present invention.

Preferably, said sun cream further comprises at least one antiviral substance. Here, the same antiviral substance as mentioned above for the pharmaceutical composition will be preferred.

According to a further embodiment of the present invention a vaccine is provided which comprises as an antigen an attenuated retrovirus as mentioned above, an env protein, a pol protein, a gag protein or a peptide as defined above according to the present invention, respectively, and optionally an adjuvant. Such a vaccine when applied to a patient will induce the production of antibodies and/or T cells, which can inhibit infectious HERVs according to the present invention. Therefore, such a vaccine is a highly effective substance for treating infectious HERV infections. The production of vaccines against retroviruses is described in "Hyperattenuated Recombinant Influenza A Virus Nonstructural-Protein-Encoding Vectors Induce Human Immunodeficiency Virus Type 1 Nef-Specific Systemic and Mucosal Immune Responses in

Mice", Boris Ferko, Jana Stasakova, Sabine Sereinig, Julia Romanova, Dietmar Katinger, Brigitte Niebler, Hermann Katinger, and Andrej Egorov. *Journal of Virology*, October 2001, p. 8899-8908, Vol. 75, No. 19, which is incorporated herein by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention is described in more detail with the help of the following examples and figures to which it should not, however, be limited.

In the drawings:

FIG. 1 shows the characterization of particle preparations from melanoma cell supernatants.

FIG. 2 shows an electron microscopy of melanoma cell-derived supernatants.

FIG. 3 shows the expression of the retroviral pol gene in melanomas.

FIGS. 4A and 4B show an immunofluorescence analysis with HERV-K-specific antibodies against gag, cORF, and env.

FIG. 5 shows cells infected with melanoma-associated particles.

FIG. 6 shows the detection of particle associated RNA and supernatants from infected MDBK cells.

FIGS. 7A and 7B show the transfer of supernatants from melanoma particle exposed MDBK cells to uninfected MDBK cells.

FIGS. 8A and 8B show the vector pCR4Topo (SEQ ID NOs:48 and 49) as well as the gag (SEQ ID NO:50), prot (SEQ ID NO:51), pol (SEQ ID NO:52) and env (SEQ ID NO:53) primers.

DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

EXAMPLES

Example 1

Human Melanoma Cells Contain RT Activity in Their Supernatants

To detect extracellular virions, supernatants from the melanoma cell lines SKMel-28, SKMel-1, 518A2 were analyzed, as well as primary melanoma cells for pelletable RT. Supernatants from cultured human neonatal melanocytes (NHEM) served as controls. Cell-free supernatants from approximately 10^6 cells were concentrated by centrifugation. The RT activity of the resulting pellets was analyzed by F-PERT assay.

Supernatants from melanoma cell lines, and normal human melanocytes were centrifuged at $3000\times g$ at $4^\circ C$. and sterile-filtered through a $0.22 \mu m$ low-protein membrane (Nunc) to remove cells and cellular debris. The clarified supernatants were centrifuged for 20 min at $250000\times g$ at $4^\circ C$. in a Beckman SW50.1 rotor. Pellets were rinsed with phosphate-buffered saline (PBS) and centrifuged for 15 min at $250000\times g$ and resuspended. The resulting particle suspensions were used as an enzyme source for RT assays.

Pelleted particles derived from 4 ml cell-free supernatants of approximately 10^6 cells were analyzed. RT activity was determined by fluorescent probe-based product enhanced RT (F-PERT) assay as described, with modifications. First, pellets were suspended in lysis buffer (Roche). Then RT was performed, using the suspended pellet as source of enzyme, the primer 3'A10 (5'-CACAGGTCAAACCGCCTAG-GAATG-3' (SEQ ID NO:54)), and 0.3 μg MS2-RNA as a

template (Roche #165948). To limit unspecific reverse transcription, 0.5 μg calf-thymus DNA (Sigma #D4522) was added. After incubation at $42^\circ C$. for 1 h, a 5 μl aliquot of this reaction was amplified by real-time PCR, by adding 25 μl TaqMan Universal PCR Master Mix (Applied Biosystems #430-4437), 1 μl of the primers 3'A10 and 5'A 11 (5'-TCCT-GCTCAACTTCCTGTCGAG-3' (SEQ ID NO:55)) at a concentration of 10 μM each, 1 μl F-PERT probe (genXpress, 10 μM , 5'(FAM)-TCTTTAGCGAGACGCTACCATGGCTA-(TAMRA)3' (SEQ ID NO:56)), and 17 μl AD. The resulting mixture was then amplified by incubating 10 mins at $95^\circ C$., followed by 40 cycles at $94^\circ C$. for 20 sec and $64^\circ C$. for 1 min, in a SD 7700 (Perkin Elmer). The calibration curve was generated by plotting the RT activity of a serial dilution of Moloney Murine Leukemia Virus (M-MLV) RT (Superscript II Gibco #18064-014). Alternatively, detection of reverse transcriptase was performed with a commercially available reverse transcription assay (Boehringer Mannheim). In this procedure, dioxigenin (DIG) and biotin-labeled nucleotides synthesized by the reverse transcriptase are incorporated into the DNA molecule. Biotin-labeled DNA is then captured to the streptavidin coated surface of the microtiter plates. In a subsequent step, an antibody to DIG conjugated to peroxidase is bound to the dioxigenin-labeled DNA. In the final step, the peroxidase substrate ABTS and a substrate enhancer were added. The absorbance of the samples was determined using a microtiter plate reader. The calibration curve was generated by plotting a serial dilution of an HIV-1 derived RT with defined activity.

Supernatants were found to contain a fluctuating yet continuously present RT activity, corresponding to the activity of up to 10000 μ units of M-MLV RT (Superscript II, Gibco) per ml supernatant. On the other hand, supernatants from cultured melanocytes did not contain detectable RT activity (detection limit 10^{-1} μ units). The fact that supernatants derived from melanoma cells but not from melanocytes contain pelletable RT activity shows that melanoma cells contain proviral sequences with sufficient genetic information to form particles containing a functional RT. Since no RT activity was detected in the supernatants of melanocytes, production of particles containing RT appears to be activated during transformation of melanocytes to malignant cells.

Example 2

Human Melanoma Cell Derived Particles Package Sequences with High Homology to HERV-K

Retroviral pol genes are generally the most conserved sequences among retroviruses. In an attempt to analyze the particle preparations on a molecular level, a sequence was amplified by using degenerate primers corresponding to conserved sequences of the pol gene. Particle preparations of the melanoma cell line 518A2 and SK-Mel28 were used for RT-PCR analysis. Particles were treated with DNase, to remove contaminating traces of genomic DNA.

Oligonucleotide primers 3'ABDPOLS 5'dCATTCCT-TGTGGTAAACTTTCCA[T/C]TG 3' (SEQ ID NO:57) and 5'ABDPOLAS 5'dCCCCTTGGAATACTCCTGTTTT [T/C]TG 3' (SEQ ID NO:58) (Codon Genetic Systems, Austria), derived from conserved regions within the retroviral reverse transcriptase (RT), were adopted from Medstrand and Blomberg. In order to release viral RNA, the particle suspension was transferred to a 0.5 ml polypropylene microcentrifuge tube (Sørensen Inc., USA). Then 10 μl of sterile water containing 0.1% Triton X-100 and 10 U RNase inhibitor (Gibco) was added and incubated at $65^\circ C$. for 10 min. The reverse transcription was performed in the same tubes. A

mixture containing 50 mM Tris-HCl buffer pH 8.3, 50 mM KCl, 7.5 mM MgCl₂, 5 mM DTT, 1 mM dNTPs, 20 pmol primer 3'ABDPOLA, 10 U RNase inhibitor and 100 U of Superscript II RT (Gibco) in a final volume of 20 µl was added while the tubes were kept on ice. The reaction was performed at 42° C. for 45 min.

For PCR, the reaction mixture contained 10 mM Tris-HCl buffer pH 8.3, 50 mM KCl, 1.5 mM MgCl₂, 0.005% (w/v) gelatin, 0.2 mM dNTPs, 25 pmol of 3'ABDPOLS and 5'ABDPOLAS, 10 µl of the reverse transcription reaction and 1.25 U Taq polymerase (Boehringer Mannheim) in a final volume of 50 µl. The reaction mixtures were overlaid with mineral oil and subjected to 3 thermal cycles of denaturation at 92° C. for 45 s, primer annealing at 45° C. for 45 s and elongation at 72° C. for 60 s, followed by 45 cycles at 92° C. for 45 s, 55° C. for 45 s and 72° C. for 60 s. 10 µl of each amplification product, were analyzed by electrophoresis in a 1.5% agarose gel and visualized by ethidium bromide staining. An aliquot of the amplification product was cloned and sequenced.

RT-PCR of these preparations revealed the anticipated amplification products of 298 nucleotides. Since no amplification products were obtained when RT was omitted, possible DNA contaminations can be excluded (FIG. 1a). (A) RT-PCR. Particle preparations of the melanoma cell line Mel-Juso were treated with DNase and used for analysis. PCR (lane 1) or RT-PCR (lane 2) with degenerate primers corresponding to sequences that are conserved in retroviral polymerase (pol) genes was performed; M, molecular weight marker (Boehringer Mannheim VIII). No amplification products were obtained in the control reactions without RT, demonstrating the absence of contamination with DNA (lane 1). In contrast, RT-PCR revealed the anticipated amplification products of 298 nucleotides (lane 2). (B) Immunoblotting. Particle preparations from SK-Mel28 supernatants were separated by SDS-PAGE, blotted and HERV-K-specific proteins were detected with antiserum recognizing env (lane 1), gag (lane 3) and the corresponding pre-immunesera, pre-env (lane 2) and pre-gag (lane 4). Molecular weight is indicated to the left. In addition, RT-PCR of the GAPDH gene was negative, reflecting the lack of contamination with cellular mRNA (data not shown). The amplification product was cloned into an expression vector and sequenced. Sequence analysis revealed that the amplified fragment shows high homology to the corresponding pol region of endogenous retrovirus HERV-K. Translation of the obtained nucleotide sequence revealed the amino acid sequence IKKKSGKWRMLTDLRAINSVIQPMGALQPGLPSPAIIIPKN-WPLVVIDLKDSFFTIPL ADQDCEWF AFIIPAVNNLQ-PAKHF (SEQ ID NO:59). This sequence is highly homologous with the corresponding sequences of the HERV-K HML2 and HML3 families. Within these groups the highest identity (90%) was observed for clone NMWV5 (GenBank accession AF0115998). Homology to sequences of type A, B and C retroviruses was less than 70%. The sequence analysis excludes contamination with any known non-human retrovirus and suggests an endogenous origin of the packaged RNA.

Example 3

Human Melanoma Derived Particles Contain Mature Gag and Env Proteins

Particles derived from SK-Mel28 melanoma cells were purified on iodixanol-cushions and analyzed for the presence of HERV-K-specific env and gag proteins in Western blots.

Iodixanol-cushion purified particles from SK-Mel28 supernatants were pelleted, resuspended in PBS and ana-

lyzed. The amount of soluble proteins was quantified by means of a modified Bradford analysis (Bio-rad, Richmond Calif.). 5 µg of total protein was applied per lane and separated by SDS-PAGE (10%). Proteins were transferred to PVDF membranes (Millipore, Bedford, Mass.) by Western blotting, and generated blots were incubated with the gag- and env-specific antisera. The membranes were washed twice with blocking solution and HERV-K-specific proteins were detected with an alkaline-phosphatase-conjugated second-step antibody.

The envelope (env) gene of retroviruses displays an ORF for the surface protein (SU) and a membrane spanning protein (TM). The env precursor is usually cleaved into the SU and TM subunits before translocation to the cell surface and incorporation into virus particles. To determine whether the env protein is present on the particles, immunoblotting with an antiserum recognizing the TM domain was performed. As shown in FIG. 1b two bands are visible in the Western blot. The upper band corresponds to the precursor migrating at approximately 80 to 90 kDa. In addition, a lower band migrating at approximately 37 kDa is visible, suggesting cleavage of the precursor into subunits.

Immunoblotting with an HERV-K anti-gag antiserum revealed a double band at approximately 76 kDa, corresponding to gag precursors, as well as processed intermediate gag proteins at approximately 61 kDa, 30 kDa and one band migrating with the front (less than 19 kDa). The 30 kDa protein corresponds to the putative major core protein of HERV-K. The presence of processed gag proteins in the Western blots indicates a functional protease.

Example 4

Human Melanoma Cells Produce Retrovirus-Like Particles

To confirm the presence of particles electron microscopy (EM) was performed.

15 µl aliquots of iodixanol-density gradient purified particle suspensions from SK-Mel28 supernatants were applied on Formvar coated grids and left there for 15 min. Excess suspension was removed from the edges of the grids by filter paper. The grid with the remaining sample was air dried for 1 h. The sample was either directly exposed to 1% uranyl acetate for negative staining or, for immunoelectron microscopy, fixed in paraformaldehyde-lysine-periodate for 15 min, rinsed in distilled water, quenched in PBS/1% BSA and incubated in anti-env antiserum diluted 1:25 in PBS/1% BSA for 1 h at RT. After washing, the grid was exposed to 5 nM colloidal gold conjugated rabbit anti-goat antibody (British Biocell, Cardiff, UK) diluted 1:50 in PBS/1% BSA for 1 h. After fixation in 2.5% glutaraldehyde, washing and negative staining with 1% uranyl acetate, the grid was left to air dry. All grids were examined with a JEOL 1010 electron microscope.

For electron microscopy, immunoblotting and infection studies, cell-free supernatants were purified on iodixanol density gradients or cushions. Iodixanol is an iodinated, non-ionic density gradient medium (Nycomed Pharma, Oslo, Norway). It has a low viscosity and provides iso-osmotic conditions up to densities of 1.32 g/ml. The supernatants were overlaid on a cushion of 5 ml 50% iodixanol. The tubes were centrifuged in an SW28 rotor at 45000×g for 2 h at 4° C. and the supernatant was removed from the tubes by suction, leaving a volume of 4 ml of the medium in proximity of the cushion. This fraction was harvested, pelleted in a SW41 rotor at 150000×g for 90 min at 4° C., resuspended in PBS and analyzed. Alternatively, for further purification the cushion-derived fraction was loaded on iodixanol density gradients, and the fraction corresponding to a density of approximately

21

1.16 g/ml was harvested. The harvested fractions were diluted in PBS and pelleted in a SW41 rotor at 150000×g for 90 min at 4° C. and resuspended in PBS.

Pellets were partially purified on iodixanol-cushions (FIG. 2, upper part). Alternatively, these fractions were further purified on iodixanol density-gradients (FIG. 2, lower part). These preparations were analyzed by immunoelectron microscopy using an env-specific antiserum and a colloidal gold conjugated reporter antibody. EM analysis of these preparations revealed the presence of retrovirus-like particles characterized by membrane bound spherical structures with diameters ranging between 80 and 120 nm. The presence of immunogold on the particles indicates that the env protein is present in the envelope.

Example 5

The Pol Gene is Expressed in Tumor Cells Derived from Melanomas

The integration sites of human endogenous retroviral elements have been found to be distributed over the whole human genome. For example, the HERV-K family was reported to be present in approximately 30 copies per human haploid genome. Based on the observation that melanoma cells (but not melanocytes) produce retrovirus-like particles, it can be hypothesized that the formation of virus-like particles might be due to the activation of retroviral genes that are usually repressed. Therefore the cloned pol sequence derived from the particle preparations was used as a probe and looked for expression of this sequence in the cytoplasm of melanoma cells by in situ hybridization.

Touch preparations of a nevus, primary melanoma, and melanoma metastasis were made by dipping freshly excised tissue on coated slides (DAKO, Biotek Solutions). Slides were fixed in 4% paraformaldehyde for 20 mins, washed in PBS, dehydrated through graded alcohols to absolute ethanol, and were air dried.

The hybridization mixtures consisted of Hybrisol VI (Onco, Gaithersburg) and DIG-labeled cDNA probes, giving a final concentration of 2 ng/μl. Slides were covered with glass coverslips and sealed with Gelbond (ICN). Probe and cellular material were denatured by heating to 80° C. for 5 mins. Hybridization was carried out at 37° C. overnight in a humid chamber. After removal of the coverslips the slides were washed at 46° C. three times with 50% formamide/2× SSC, once with 2× SSC for 10 mins, followed by a single wash step in 2× SSC containing 0.1% NP40 for 10 mins. Signal detection was performed after a blocking step in 1% blocking reagent (Boehringer Mannheim) of 30 mins at 37° C. by incubation with anti-DIG antibody, conjugated to rhodamine at a dilution of 1:10 in 1% blocking reagent for 30 mins at 37° C. in a humidified box. After extensive washings in PBS, slides were counterstained with 10 μg/ml DAPI for 20 mins and visualized with a Zeiss fluorescence microscope using a triple bandpass filter and software from PSI.

To determine the specificity of the pol sequence for melanoma, touch preparations of a nodular melanoma were analyzed, a lymph node metastasis, and a cutaneous metastasis that had been surgically removed from melanoma patients. As shown in FIG. 3 (Touch preparations from primary melanoma (a), lymph node metastasis (b), cutaneous metastasis (c), nevus (d), and a tumor free sentinel lymph node (e) surgically removed from patients were analyzed by in situ hybridization with probes specific for nucleotide sequences of the pol gene (POL), melanoma inhibiting activity gene (MIA), and the influenza virus nucleoprotein (FLU). Nucleotide sequences of the pol and the melanoma inhibiting activity genes are

22

found in primary melanoma and lymph node and cutaneous metastases but not in the nevus and tumor free lymph node), high copy numbers of the pol sequence were found in tumor cells of all melanoma preparations tested. In comparison, cells derived from the lymph node and the benign nevus of healthy individuals were negative. A probe specific for the nucleoprotein gene of influenza virus was always negative. As a positive control, a probe recognizing the melanoma-inhibiting activity gene was used. The rate of tumor cells expressing the pol gene was in the range of 60-90%, a percentage similar to the one obtained with the melanoma-inhibiting activity specific probe. The observation that the sequences are not found in all tumor cells might be due to the sensitivity of the assay and variations in the expression levels.

Example 6

Retroviral Gag, cORF, and Env Proteins are Expressed in Melanomas

To determine whether HERV-specific proteins were detectable in melanoma cells, immunofluorescence analysis with antisera recognizing the gag, cORF and env proteins of HERV-K was performed.

Cells grown on chamber slides, as well as touch preparations from a nevus and primary melanoma on coated slides (DAKO) were fixed in 4% paraformaldehyde for 20 mins, washed in PBS and dehydrated through graded alcohols to absolute ethanol and air dried. In addition, five micrometer sections prepared from routinely processed paraffin wax blocks of a nevus and melanoma were placed on coated slides (DAKO). The tissues were dewaxed in xylene, rehydrated by sequential immersion in graded ethanols and PBS and subsequently permeabilised by microwave treatment.

Immunofluorescence staining was performed by incubating chamber slides, touch preparations, and paraffin sections with HERV-K-specific antibodies at a dilution of 1:100 for 1 h at 37° C. in a humidified box, followed by washing three times with PBS and subsequent incubation with Alexafluor-488-conjugated antibodies at a dilution of 1:200 for 1 h at 37° C. Counterstaining was performed by mounting in Vectashield containing DAPI (Vector). Preparations were analyzed by using a Zeiss fluorescence microscope with appropriate filters.

FIG. 4a shows that the melanoma cell lines Mel-Juso and SK-Mel28 express the gag, cORF and env proteins. The percentage of gag-expressing cells was in the range of 1-10%, cORF was found to be present in about 20%, while expression of the env protein was detected in about 10% of the analyzed cells. Expression of gag and env was found in the cytoplasm, while cORF was mainly found in the nucleus. In contrast, cultured human melanocytes (Nhem) and Vero cells did not react with any HERV-K-specific antisera. None of the corresponding preimmune-sera was reactive with any of the cells tested.

Immunofluorescence analysis was performed with touch preparation of a primary melanoma (first column); touch preparation of a nevus (second column); paraffin preparation primary melanoma (third column); paraffin preparation nevus (fourth column). Retroviral proteins are present in the melanoma preparations but absent from nevus tissue.

It was then analyzed whether these proteins are also expressed in primary melanoma. FIG. 4b shows that gag, cORF, and env were detected in touch preparations and paraffin sections of a primary melanoma but not in the corresponding preparations of a nevus.

Example 7

Melanoma Cell Derived Particles are Infectious

Supernatants of approximately 10^8 melanoma cells were loaded on 30% sucrose cushions and centrifuged at 28K. The resulting pellets were washed and resuspended in 500 μ l PBS. For infection studies human 293 cells were grown to approximately 30% confluency and exposed overnight to the particle preparations in the presence of 8 μ g/ml polybrene. As controls, cells were treated with particle preparations that were heat inactivated 30 min at 60° C. or mock-treated. 293 cells were exposed to particle preparations from the melanoma cell line SKMel28.

The human epithelial cell line 293 is a well established target for retrovirus infection. Immunofluorescence with HERV-K specific gag antibodies was performed three weeks post infection (p.i.). Control cells were mock-treated. 293 cells were treated with the melanoma-derived viral particles, and demonstrate that upon treatment they express the HERV-K specific gag-protein (FIG. 5a). Moreover, expression of the retroviral proteins correlated with the level of pelletable RT-activity in the supernatants (FIG. 5b), suggesting that the 293 cells were infected with the melanoma-derived particles. However, due to the high copy numbers of various HERV sequences present in the human genome it was not possible to demonstrate that expression of proteins and production of RT-containing particles was derived from de novo integrated retroviral DNA into the hosts genome. Therefore this question was addressed in bovine MDBK cells.

Example 8

Infection of MDBK Cells

It was tested whether the melanoma-derived particles are infectious. Due to the high copy numbers of various HERV sequences present in the human genome it is difficult to demonstrate in human cells whether virus particles produced are derived from endogenous or exogenous virus. This question was therefore addressed in bovine MDBK cells which are free of viruses that are homologous to HERV-K. MDBK cells were exposed to melanoma derived particle preparations and passaged at a ratio of 1:10. Supernatants of these cells were analyzed by RT-PCR with pol-specific HERV primers as described below:

Cell free supernatants of approximately 10^8 518A2 melanoma cells were loaded on 20% sucrose cushions and pelleted at 28K in a Beckmann SW28 rotor. The resulting pellets were washed and resuspended in 500 μ l PBS. For infection studies bovine MDBK cells were grown to approximately 30% confluency and exposed overnight to 100 μ l aliquots of the particle preparations in the presence of 0.8% polybrene. As controls, cells were treated with particle preparations that were heat inactivated. 24 hour post infection (p.i.) the inoculum was removed, the cells were washed twice with PBS and incubated with normal media. Starting at 7 days p.i. the cells were continuously passaged at a ratio of 1:10 and the supernatants were analyzed for the presence of viral particles by detecting particle-associated RNA. In addition 1.5 ml of the supernatants from infected MDBK cells were put onto new (uninfected) MDBK cells, in the presence of polybrene. 24 hours later the cells were washed twice with PBS and incubated for 7 days, and passaged at a ratio of 1:10. The release of particles from the cells was determined by detecting particle-associated RNA in the supernatants by RT-PCR as described below:

For detecting particles released by the cells, supernatants from approximately 10^7 518A2 or infected MDBK cells were filtered, pelleted 2 hours at 28K and resuspended in 500 μ l Trizol. To this suspension 100 μ l chloroform were added. After vortexing and centrifugation the upper phase was pre-

cipitated with isopropanol. The precipitate was pelleted by centrifugation and washed with 70% ethanol. The pellet was resuspended, treated with DNase in the presence of 25 mM $MgCl_2$ for 45 min at 37° C., and the DNase was inactivated for 10 min at 65° C. After precipitation with 96% ethanol, the pellet was washed with 70% ethanol, resuspended in reverse transcription (RT) reaction buffer and RT was performed with the random primer p(dN)6.1/10 of the reverse transcription reaction was used as template for PCR with the oligonucleotide primers 5'108 propol 3925 5'CCACTGTAGAGCCTCCTAAACCC 3' (SEQ ID No 6) and 3'108 pol 4315 5' GCTGGTATAGTAAAGGCAAATTTTTC 3' (SEQ ID No 7) (Codon Genetic Systems, Austria) which correspond to conserved regions within the pol gene.

10 μ l of each amplification product were analyzed by electrophoresis in a 1.5% agarose gel and visualized by ethidium bromide staining. An aliquot of the amplification product was cloned and sequenced. Expression of HERV-specific RNA expressed in MDBK cells was detected by RT-PCR of total genomic RNA derived from approximately 10^7 cells in the same manner.

FIG. 6 shows the result after the first passage. Lanes 1-6: After infection cells were passaged 1:10 and supernatants were analyzed by RT-PCR with pol-specific primers (+). Absence of contaminating DNA was analyzed by omitting the RT step (-); Lane 1, no template control; lane 2, heat inactivated particles; lane 3, particle preparation diluted 1:100, lane 4, 1:10 dilution, lane 5, undiluted particle preparations; lane 6, 518A2 supernatant; M, molecular weight marker; Analysis of genomic DNA with pol-specific primers by PCR. Lane 1, no template control; lane 2, no template control; lane 3, MDBK DNA; lane 4, 518A2 DNA, lane 5, no enzyme control. Infection with undiluted particle preparations revealed a pol-specific amplification product (lane 5, +), while infection with particle preparations that were diluted 1:10 (lane 4+), diluted 1:100 (lane 3+) or were heat inactivated (lane 2+) did not. None of the reactions revealed a signal when the RT step was omitted, excluding that the signals were derived from genomic DNAs contaminations (lanes 2-6, -). The presence of particle associated viral sequences in the supernatant of the melanoma-derived particle exposed MDBK cells indicates that melanoma-derived particles are capable to infect bovine cells.

Sequence analysis of the amplification product of lane 5 revealed the nucleotide sequence

(SEQ ID No 8)
 5' CCACTGTAGAGCCTCCTAAACCCATACCATTAAGTGGAAAACAGAAA
 AACCGGTGTGGGTAAATCAGTGGCCGCTACCAAAACAAAACTGGAGGCT
 TTACATTTATTAGCAAATGAACAGTTAGAAAAGGGTCATATTGAGCCTTC
 GTTCTCACCTTGGAAATTCTCCTGTGTTTGTAAATTCAGAAGAAATCAGGCA
 AATGGCATATGTTAACTGACTTAAAGGCCGTAAACGCCGTAATTCAACCC
 AT 3'.

This sequence is highly homologous (98%) to the sequence from HERV-K 108.

Example 9

Supernatants from Infected MDBK Cells Contain Infectious Particles

Cell free supernatants from cells exposed to undiluted melanoma particle preparations were put onto new (uninfected) MDBK cells which were subsequently passaged 3 times at a ratio of 1:10

FIG. 7 shows the transfer of supernatants from melanoma-particle exposed MDBK cells to uninfected MDBK cells. 24 hours later cells were washed twice with PBS, incubated for one week, and subsequently passaged at a ratio of 1:10. FIG. 7a shows pelleted supernatants from these cells which were analyzed for release of particle-associated RNA by RT-PCR with pol-specific primers (lanes 1, 3, 5, 7). As negative controls supernatants from MDBK cells exposed to heat inactivated particles were transferred to MDBK cells which were treated and analyzed in the same manner (lanes 2, 4, 6, 8). Lanes 1 and 2: 5 days after transfer; lanes 3 and 4: passage 1; lanes 5 and 6: passage 2; lanes 7 and 8: passage 3; lane M: molecular weight marker (Boehringer Mannheim VIII); lane 9: negative control: pelleted supernatant from uninfected MDBK cells; lane 10: positive control: pelleted supernatants from 518A2 cells; FIG. 7b shows the expression of HERV-specific RNAs which was analyzed by RT-PCR from whole genomic RNA of MDBK cells from passage 1 with pol-specific primers. Lane 1: MDBK cells treated with supernatants from infected MDBK cells; lane 2: MDBK cells treated with supernatants from MDBK cells exposed to heat inactivated melanoma-derived particle preparations; lane M, molecular weight marker (Boehringer Mannheim VIII); lane 3, negative control: PCR of genomic DNA derived from uninfected MDBK cells; lane 4, positive control: PCR of genomic DNA derived from 518A2 cells; lane 5: non-template control. Lanes 1, 3, 5, and 7 correspond to passages 0, 1, 2, and 3 respectively. Lanes 2, 4, 6, and 8 are the negative controls and correspond to passages 0, 1, 2, and 3 of cells treated with supernatants from cells exposed to heat inactivated particle preparations.

Shown is the presence of particle associated RNA as indicated by the presence of a pol-specific sequences. Pol-specific signals were detectable after passages 0, 1, and 3, suggesting the presence of viral particles (lanes 1, 3, and 7). Analysis of passage number 2 did not reveal a pol-signal which might be

due to fluctuating production levels of viral particles (lane 5). Transfer of supernatants from MDBK cells that were treated with heat inactivated particle preparations did not result in the release of particles (lanes 2, 4, 6, and 8). PCR alone did not reveal pol-specific signals, indicating that the signals obtained by RT-PCR are derived from RNA. The result that transfer of the supernatant from infected MDBK cells to uninfected MDBK cells resulted in the release of particle associated viral RNA, indicates that infection with melanoma derived particles of MDBK cells is productive.

These data show that retroviral sequences and infectious particles are expressed in melanoma cells.

Partial sequence analysis, immunoblotting and immunoelectron microscopy studies show the particles belong to the HERV-K family. In contrast to other known HERV-K like viruses, which lack infectivity, the env precursor appears to be cleaved in the melanoma derived particles, resulting in approximately equimolar amounts of the precursor and the putative transmembrane domain. Cell-free particle preparations from the melanoma cells were able to infect both human and bovine cells, as indicated by the appearance of the viral proteins gag, cORF, and env, and pelletable RT-activity in the supernatants of infected cells. Moreover, the fact that human pol and gag sequences in the genome of the infected bovine MDBK cells were detected, indicates that the melanoma-associated viruses are capable of de novo integration of their genome. This observation also suggests the presence of a functional integrase in the viral particles.

FIG. 8a shows the pCR4-Topo vector into which the MERV gag, pro, pol and env sequences isolated from the above described infected bovine cells were inserted. The primers used in the above examples are shown in the boxes of each sequence of vectors shown in FIG. 8b. These vectors were deposited on 26 Sep. 2001 at the DSMZ under the names MERV-env, MERV-gag, MERV-prt and MERV-pol according to the Budapest Treaty.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 59

<210> SEQ ID NO 1

<211> LENGTH: 7475

<212> TYPE: DNA

<213> ORGANISM: Human endogenous retrovirus

<400> SEQUENCE: 1

```

gctaggggtga taatggggca aactaaaagt aaaattaaaa gtaaatatgc ctcttatctc      60
agctttatta aaattctttt aaaaagaggg ggagttaaag tatctacaaa aaatctaate      120
aagctatttc aaataataga acaattttgc ccatggtttc cagaacaagg aactttagat      180
ctaaaagatt ggaaaagaat tggttaaggaa ctaaaacaag caggtaggaa gggtaatatc      240
attccactta cagtatggaa tgattgggcc attattaaag cagctttaga accatttcaa      300
acagaagaag atagcgtttc agtttctgat gccctggaa gctgtataat agattgtaat      360
gaaaacacaa ggaaaaaatc ccagaaagaa acggaagggtt tacattgcga atatgcagca      420
gagccggtaa tggctcagtc aacgcaaaat gttgactata atcaattaca ggaggtgata      480
tatcctgaaa cgttaaaatt agaaggaaaa ggtccagaat tagtggggcc atcagagtct      540
aaaccacgag gcacaagtcc tttccagca ggtcagggtgc ctgtaacatt acaacctcaa      600
acgcaggtta aagaaaataa gaccaacca ccagtagctt atcaatactg gccgccggct      660

```

-continued

gaacttcagt atcgccacc cccagaaagt cagtatggat atccaggaat gccccagca	720
ccacagggca gggcgccgta ccctcagccg cccactagga gacttaatcc tacggcacca	780
cctagtagac agggtagtga actacatgaa attattgata aatcaagaaa ggaaggagat	840
actgagggcat ggcaattccc agtaatgtta gaaccgatgc cacctggaga aggagcccaa	900
gagggagagc ctcccacagt tgaggccaga tacaagtctt tttcaataaa aatgctaaaa	960
gatatgaaaag aaggagtaaa acagtatgga cccaactccc cttatatgag gacattatta	1020
gattccattg ctcatggaca tagactcatt ccttatgatt gggagattct ggcaaaatcg	1080
tctctctcac cctctcaatt tttacaattt aagacttggg ggattgatgg ggtacaagaa	1140
caggtccaaa gaaatagggc tgccaatcct ccagttaaca tagatgcaga tcaactatta	1200
ggaataggtc aaaattggag tactattagt caacaagcat taatgcaaaa tgaggccatt	1260
gagcaagtta gagctatctg ccttagagcc tgggaaaaaa tccaagacc aggaagtacc	1320
tgcccctcat ttaatacagt aagacaaagt tcaaaagagc cctatcctga ttttgtggca	1380
aggctccaag atgttgctca aaagtcaatt gccgatgaaa aagcccgtaa ggtcatagtg	1440
gagttgatgg catatgaaaa cgccaatcct gagtgtcaat cagccattaa gccattaaaa	1500
ggaaaaggttc ctgcaggatc agatgtaatc tcagaatatg taaaagcctg tgatggaatc	1560
ggaggagcta tgcataaagc tatgcttatg gctcaagcaa taacaggagt tgttttagga	1620
ggacaagtta gaacatttgg aggaaaatgt tacaattgtg gtcaaatcgg tcaactaaaa	1680
aagaattgcc cagtcttaa caaacagaat ataactattc aagcaactac aacaggtaga	1740
gagccacctg acttatgtcc aagatgtaaa aaaggaaaac attgggctag tcaatgtcgt	1800
tctaaatttg ataaaaatgg gcaaccattg tcgggaaacg agcaaagggg ccagcctcag	1860
gccccacaac aaactggggc attcccatt cagccatttg ttccctcaggg ttttcaggga	1920
caacaacccc cactgtcca agtgtttcag ggaataagcc agttaccaca atacaacaat	1980
tgccccccac cacaagcggc agtgcagcag tagatttatg tactatacaa gcagtctctc	2040
tgcttccagg ggagccccca caaaaaatcc ccacaggggt atatggccca ctgctgaga	2100
ggactgtagg actaatcttg ggaagatcaa gtctaaatct aaaaggagtt caaattcata	2160
ctgggtgtgg tgattcagac tataaaggcg aaattcagtt ggttattagc tcttcaattc	2220
ctggagtg cagtccagga gacaggattg ctgaattatt actcctgcca tatattaagg	2280
gtggaaatag tgaataaaaa agaacaggag ggtttggaag cactgatccg acaggaaagg	2340
ctgcatattg ggcaagtcag gtctcagaga acagacctgt gtgtaaggcc attattcaag	2400
gaaaacagtt tgaagggttg gtagacactg gagcagatgt ctctatcatt gctttaaatc	2460
ggtggccaaa aaattggcct aacccaaaagg ctgttacagg acttgctggc ataggcacag	2520
cctcagaagt gtatcaaagt acggagattt tacattgctt agggccagat aatcaagaaa	2580
gtactgttca gccaatgatt acttcaattc ctcttaatct gtggggtcga gatttattac	2640
aacaatgggg tgcgaaatc accatgcccg ctccatcata tagccccacg agtcaaaaa	2700
tcatgaccaa gatgggatat ataccaggaa agggactagg gaaaaatgaa gatggcatta	2760
aaattccagt tgaggctaaa ataatcaag aaagagaagg aatagggtat cctttttagg	2820
ggcggccact gtagagcctc ctaaaccat accattaact tggaaaacag aaaaaccgg	2880
gtgggtaaat cagtggccgc taccaaaaca aaaactggag gctttacatt tattagcgaa	2940
tgaacagtta gaaaagggtc atattgagcc ttcatctca ccttgaatt ctctgtgtt	3000
tgtaattcag aagaaatcag gcaaatggcg tatgttaact gacttaaggg ccgtaaacgc	3060

-continued

cgtaattcaa	cccatggggc	ctctccaacc	tggttgccc	tctctggcca	tgatcccaaa	3120
agactggcct	ttaattataa	ttgatctaaa	ggattgcttt	tttaccatcc	ctctggcgga	3180
gcaggattgc	gaaaaatttg	cctttactat	accagccata	aataataaag	aaccagccac	3240
caggtttcag	tggaaagtgt	tacctcaggg	aatgcttaat	agtccaacta	tttgtcagac	3300
ttttgtaggt	cgagctcttc	aaccagttag	agaaaagttt	tcagactggt	atattattca	3360
ttatattgat	gatattttat	gtgctgcaga	aacgaaagat	aaattaattg	actggtatac	3420
atctctgcaa	gcagaggttg	ccaatgctgg	actggcaata	gcatctgata	agatccaaac	3480
ctctactcct	tttcattatt	tagggatgca	gatagaaaat	agaaaaatta	agccacaaaa	3540
aatagaaata	agaaaagaca	cattaanaaac	actaaatgat	tttcaaaaat	tactaggaga	3600
tattaattgg	attcggccaa	ctctagcat	tctacttat	gccatgtcaa	atttggtctc	3660
tatcttaaga	ggagactcag	acttaaatag	taaaagaatg	ttaaccacag	aggcaacaaa	3720
agaaattaaa	ttagtggaag	aaaaaattca	gtcagcgcaa	ataaatagaa	tagatccctt	3780
agccccactc	caacttttga	tttttgccac	tgacattct	ccaacaggca	tcattattca	3840
aaatactgat	cttgtggagt	ggtcattcct	tctcaccagt	acagttaaga	cttttacatt	3900
gtacttggat	caaatagcta	cattaatcgg	tcagacaaga	ttacgaataa	taaaattatg	3960
tgggaatgac	ccagacaaaa	tagttgtccc	ttaaccaag	gaacaagtta	gacaagcctt	4020
tatcaattct	ggtgcatgga	agattggtct	tgctaatttt	gtgggaatta	ttgataatca	4080
ttacccaaaa	acaagatct	tccagttctt	aaaattgact	acttgattc	tacctaaaat	4140
taccagacgt	gaaccttag	aaaatgctct	aacagtattt	actgatggtt	ccagcaatgg	4200
aaaagcagct	tacacaggac	cgaaagaacg	agtaatcaaa	actccatc	aatcggtca	4260
aagagcagag	ttggttgacg	tcattacagt	gttacaagat	tttgaccaac	ctatcaatat	4320
tatatcagat	tctgcatatg	tagtacaggc	tacaagggat	gttgagacag	ctctaattaa	4380
atatagcag	gatgatcag	taaaccagct	attcaattta	ttacaacaaa	ctgtaagaaa	4440
aagaaatttc	ccattttata	ttacacatat	tcgagcacac	actaatttac	cagggccttt	4500
gactaaagca	aatgaacaag	ctgacttact	ggtatcatct	gcactcataa	aagcacaaga	4560
acttcatgct	ttgactcatg	taaatgcagc	aggattaaaa	aacaaatttg	atgtcacatg	4620
gaaacaggca	aaagatattg	tacaacattg	caccagtggt	caagtcttac	acctgcccac	4680
tcaagaggca	ggagttaatc	ccagaggtct	gtgtcctaat	gcattatggc	aaatggatgt	4740
cacgcagta	ccttcatttg	gaagattatc	atatgttcac	gtaacagttg	atacttattc	4800
acatttcata	tgggcaactt	gccaaacagg	agaaagtact	tcccatgtta	aaaaacattt	4860
attgtcttgt	tttgctgtaa	tgggagttcc	agaaaaaatc	aaaactgaca	atggaccagg	4920
atattgtagt	aaagctttcc	aaaaattctt	aagtcaagg	aaaatttcac	atacaacagg	4980
aattccttat	aattccaag	gacaggccat	agttgaaaga	actaatagaa	caactcaaac	5040
tcaattagtt	aaacaaaaag	aagggggaga	cagtaaggag	tgtaccactc	ctcagatgca	5100
acttaatcta	gcactctata	ctttaaattt	tttaaacatt	tatagaaatc	agactactac	5160
ttctgcagaa	caacatctta	ctggtaaaaa	gaacagccca	catgaaggaa	aactaatttg	5220
gtggaaagat	aataaaaaata	agacatggga	aataggggaag	gtgataacgt	gggggagagg	5280
ttttgcttgt	gtttcaccag	gagaaaatca	gcttctgtt	tggataacca	ctagacattt	5340
gaagttctac	aatgaacca	tcagagatgc	aaagaaaagc	acctccgagg	agacggagac	5400
accgcaatcg	agcaccgttg	actcacaaga	tgaacaaaat	ggtgacgtca	gaagaacaga	5460

-continued

tgaagttgcc atccaccaag aaggcagagc cgccaacttg ggcacaacta aagaagctga	5520
cgcagttagc tacaaaaatat ctagagaaca caaagggtgac acaaacccca gagagtatgc	5580
tgcttgccagc cttgatgatt gtatcaatgg tggtaagtct ccctatgcct gcaggagcag	5640
ctgcagctaa ctatacctac tgggcctatg tgcctttccc gcccttaatt cgggcagtc	5700
catggatgga taatcctata gaagtatatg ttaatgatag tgtatgggta cctggcccca	5760
tagatgatcg ctgcctgcc aaacctgagg aagaagggat gatgataaat atttcattg	5820
ggtatcatta tcctcctatt tgcctagggga gagcaccagg atgtttaatg cctgcagtcc	5880
aaaattgggt ggtagaagta cctactgtca gtcccatctg tagattcact tatcacatgg	5940
taagcgggat gtcactcagg ccacgggtaa attatttaca agacttttct tatcaaagat	6000
cattaaaatt tagacctaaa gggaaacctt gccccaagga aattcccaa gaatcaaaaa	6060
atacagaagt tttagtttg gaagaatgtg tggccaatag tgcggtgata ttacaaaaca	6120
atgaattcgg aactattata gattgggcac ctgcaggtca attctaccac aattgctcag	6180
gacaaactca gtcgtgtcca agtgcacaag tgagtccagc tgttgatagc gacttaacag	6240
aaagtttaga caaacataag cataaaaaat tgcagtcttt ctacccttgg gaatggggag	6300
aaaaaggaat ctctaccca agaccaaaa tagtaagtcc tgtttctggt cctgaacatc	6360
cagaattatg gaggcttact gtggcctcac accacattag aatttggctt ggaaatcaaa	6420
ctttagaac aagagatcgt aagccatfff atactgtcga cctaaattcc agtctaacag	6480
ttcctttaca aagttgcgta aagccccctt atatgctagt ttaggaaat atagttatta	6540
aaccagactc ccagactata acctgtgaaa attgtagatt gcttacttgc attgattcaa	6600
cttttaattg gcaacaccgt attctgctgg tgagagcaag agagggcgtg tggatccctg	6660
tgcccatgga ccgaccgtgg gaggcctcgc catccgtcca tattttgact gaagtattaa	6720
aaggtgtttt aatagatcc aaaagattca tttttacttt aattgcagtg attatgggat	6780
taattgcagt cacagctacg ggtgctgtag caggagttgc attgcactct tctgttcagt	6840
cagtaaaactt tgttaatgat tggcaaaaaa attctacaag attgtggaat tcacaatcta	6900
gtattgatca aaaattggca aatcaaatta atgatcttag acaaactgtc atttggatgg	6960
gagacagact catgagctta gaacatcgtt tccagttaca atgtgactgg aatcagtcag	7020
atttttgtat tacaccccaa atttataatg agtctgagca tccctgggac atgggttagac	7080
gccatctaca ggaagagaa gataatctca ctttagacat ttccaaatta aaagaacaaa	7140
ttttcaaagc atcaaaagcc catttaaat tgggtgccagg aactgaggca attgcaggag	7200
ttgctgatgg cctcgcaaat cttaaccttg tcaactgggt taagaccatt ggaagtacta	7260
caattataaa tctcatatta atccttgtgt gcctgttttg tctgttgta gtctgcaggt	7320
gtaccaaca gctccgaag gacagcaacc atcgagaacg ggccatgatg acgatggcgg	7380
ttttgtcaaa aagaaaagg ggaatgtgg ggaagcaaa gagagatcag attgtcactg	7440
tgtctgtgta gaaagaagta gacataggag actcc	7475

<210> SEQ ID NO 2

<211> LENGTH: 2129

<212> TYPE: DNA

<213> ORGANISM: Human endogenous retrovirus

<400> SEQUENCE: 2

ctacaatgaa cccatcagag atgcaaagaa aagcacctcc gcggagacgg agacaccgca	60
atcgagcacc gttgactcac aagatgaaca aatgggtgac gtcagaagaa cagatgaagt	120

-continued

tgccatccac caagaaggca gagccgcca cttgggcaca actaaagaag ctgacgcagt	180
tagctacaaa atatctagag aacacaaagg tgacacaaac cccagagagt atgctgcttg	240
cagccttgat gattgtatca atgggtgtaa gtctccctat gcctgcagga gcagctgcag	300
ctaactatac ctactgggcc tatgtgcctt tcccgcctt aattcgggca gtcacatgga	360
tggataatcc tatagaagta tatgttaatg atagtgtatg ggtacctggc cccatagatg	420
atcgctgccc tgccaaacct gaggaagaag ggatgatgat aaatatttcc attgggtatc	480
attatcctcc tatttgctta gggagagcac caggatgttt aatgcctgca gtccaaaatt	540
ggttggtaga agtacctact gtcagtccca tctgtagatt cacttatcac atggtaagcg	600
ggatgtcact caggccacgg gtaaattatt tacaagactt ttcttatcaa agatcattaa	660
aatttagacc taaagggaag ccttgcccca aggaaattcc caaagaatca aaaaatacag	720
aagttttagt ttgggaagaa tgtgtggcca atagtgcggt gatattacaa aacaatgaat	780
tcggaactat tatagattgg gcacctcgag gtcaattcta ccacaattgc tcaggacaaa	840
ctcagtcgtg tccaagtgca caagtgagtc cagctgttga tagcgactta acagaaagtt	900
tagacaaaca taagcataaa aaattgcagt ctttctacct ttgggaatgg ggagaaaaag	960
gaatctctac cccaagacca aaaatagtaa gtctgtttc tggctctgaa catccagaat	1020
tatggaggct tactgtggcc tcacaccaca ttagaatttg gtctggaaat caaactttag	1080
aaacaagaga tcgtaagcca ttttatactg tcgacctaaa ttccagteta acagttcctt	1140
tacaaagttg cgtaaagccc ccttatatgc tagttgtagg aaatatagtt attaaaccag	1200
actcccagac tataacctgt gaaaattgta gattgcttac ttgcattgat tcaactttta	1260
attggcaaca ccgtattctg ctggtgagag caagagaggg cgtgtggatc cctgtgtcca	1320
tggaccgacc gtgggaggcc tcgcatccg tccatatttt gactgaagta ttaaaaggtg	1380
ttttaaatag atccaaaaga ttcattttta ctttaattgc agtgattatg ggattaattg	1440
cagtcacagc tacgggtgct gtagcaggag ttgcattgca ctcttctgtt cagtcagtaa	1500
actttgttaa tgattggcaa aaaaattcta caagattgtg gaattcacia tctagtattg	1560
atcaaaaatt ggcaaatcaa attaatgatc ttagacaaac tgtcatttgg atgggagaca	1620
gactcatgag cttagaacat cgtttccagt tacaatgtga ctggaatagc tcagattttt	1680
gtattacacc ccaaatttat aatgagtctg agcatcactg ggacatggtt agacgccatc	1740
tacaggaag agaagataat ctcaacttag acatttccaa attaaaagaa caaattttca	1800
aagcatcaaa agccattta aatttggtgc caggaactga ggcaattgca ggagttgctg	1860
atggcctcgc aaatctaac cctgtcactt gggtaagac cattggaagt actacaatta	1920
taaactctcat attaactctt gtgtgcctgt tttgtctgtt gttagtctgc aggtgtaccc	1980
aacagctctg aaggacagc aaccatcgag aacgggcat gatgacgatg gcggttttgt	2040
caaaaagaaa agggggaat gtggggaaa gcaagagaga tcagattgtc actgtgtctg	2100
tgtagaaaga agtagacata ggagactcc	2129

<210> SEQ ID NO 3

<211> LENGTH: 2180

<212> TYPE: DNA

<213> ORGANISM: Human endogenous retrovirus

<400> SEQUENCE: 3

gaaaaatttg cctttactat accagccata aataataaag aaccagccac caggtttcag	60
tggaaagtgt tacctcaggg aatgcttaat agtccaacta tttgtcagac tttttaggt	120

-continued

cgagctcttc aaccagttag agaaaagttt tcagactggt atattattca ttatattgat	180
gatattttat gtgctgcaga aacgaaagat aaattaattg actggttatac atttctgcaa	240
gcagagggtg ccaatgctgg actggcaata gcatctgata agatccaaac ctctactcct	300
tttcattatt tagggatgca gatagaaaat agaaaaatta agccacaaaa aatagaaata	360
agaaaagaca cattaanaac actaaatgat tttcaaaaat tactaggaga tattaattgg	420
attcggccaa ctctaggcat tcctacttat gccatgtaa atttgttctc tatcttaaga	480
ggagactcag acttaaatag taaaagaatg ttaaccccag aggcaacaaa agaaattaaa	540
ttagtggaag aaaaaattca gtcagcgcaa ataaatagaa tagatccctt agccccactc	600
caacttttga tttttgccac tgcacattct ccaacaggca tcattattca aaatactgat	660
cttgtggagt ggtcattcct tcctcacagt acagttaaga cttttacatt gtacttggat	720
caaatagcta cattaatcgg tcagacaaga ttacgaataa taaaattatg tgggaatgac	780
ccagacaaaa tagttgtccc tttaaccaag gaacaagtta gacaagcctt tatcaattct	840
ggtgcatgga agatttgtct tgctaatttt gtgggaatta ttgataatca ttacccaaaa	900
acaaagatct tccagttctt aaaattgact acttggattc tacctaaaat taccagacgt	960
gaacctttag aaaatgctct aacagtattt actgatggtt ccagcaatgg aaaagcagct	1020
tacacaggac cgaagaacg agtaatcaaa actccatata aatcggctca aagagcagag	1080
ttggttgca gtcattacagt gttacaagat tttgaccaac ctatcaatat tatatcagat	1140
tctgcatatg tagtacaggc tacaagggat gttgagacag ctctaattaa atatagcatg	1200
gatgatcagt taaaccagct attcaattta ttacaacaaa ctgtaagaaa aagaaatttc	1260
ccattttata ttacacatat tcgagcacac actaatttac cagggccttt gactaaagca	1320
aatgaacaag ctgacttact ggtatcatct gcactcataa aagcacaaga acttcatgct	1380
ttgactcatg taaatgcagc aggattaaaa aacaaatttg atgtcacatg gaaacaggca	1440
aaagatattg tacaacattg caccagtggt caagtcttac acctgccac tcaagaggca	1500
ggagttaatc ccagaggtct gtgtcctaata gcattatggc aaatggatgt cacgcatgta	1560
ccttcatttg gaagattatc atatgttcac gtaacagttg atacttattc acatttcata	1620
tgggcaactt gccaaacagg agaaagtact tcccatgtta aaaaacattt attgtcttgt	1680
tttctgttaa tgggagttcc agaaaaaatc aaaactgaca atggaccagg atattgtagt	1740
aaagctttcc aaaaattctt aagtcagtggt aaaatttcac atacaacagg aattccttat	1800
aattcccaag gacaggccat agttgaaaga actaatagaa cactcaaac tcaattagtt	1860
aaacaaaaag aagggggaga cagtaaggag tgtaccactc ctgagatgca acttaatcta	1920
gcactctata ctttaaattt tttaaacatt tatagaaatc agactactac ttctgcagaa	1980
caacatctta ctggtaaaaa gaacagccca catgaaggaa aactaatttg gtggaaagat	2040
aataaaaaata agacatggga aataggggaag gtgataacgt gggggagagg ttttgcttgt	2100
gtttcaccag gagaaaatca gcttcctggt tggataccca ctgacattt gaagttctac	2160
aatgaacca tcagagatgc	2180

<210> SEQ ID NO 4
 <211> LENGTH: 2013
 <212> TYPE: DNA
 <213> ORGANISM: Human endogenous retrovirus

<400> SEQUENCE: 4

gctagggatga taatggggca aactaaaagt aaaattaaaa gtaaatatgc ctcttatctc	60
--	----

-continued

```

agctttatta aaattctttt aaaaagaggg ggagttaaag tatctacaaa aaatctaatac 120
aagctatttc aaataataga acaattttgc ccatggtttc cagaacaagg aacttttagat 180
ctaaaagatt ggaaaagaat tggtaaggaa ctaaaacaag caggtaggaa gggtaatatc 240
attccactta cagtatggaa tgattgggcc attattaaag cagctttaga accatttcaa 300
acagaagaag atagcgtttc agtttctgat gccctggaa gctgtataat agattgtaat 360
gaaaacacaa ggaaaaaatc ccagaaagaa acggaagggt tacattgcga atatgcagca 420
gagccggtaa tggctcagtc aacgcaaaat gttgactata atcaattaca ggaggtgata 480
tatcctgaaa cgttaaaatt agaaggaaaa ggtccagaat tagtggggcc atcagagtct 540
aaaccacgag gcacaagtcc tcttcagca ggtcaggtgc ctgtaacatt acaacctcaa 600
acgcaggtta aagaaaataa gaccaacca ccagtagctt atcaatactg gccgccggct 660
gaacttcagt atcggccacc ccagaaagt cagtatggat atccaggaat gccccagca 720
ccacagggca gggcgccgta ccctcagccg cccactagga gacttaatcc tacggcacca 780
cctagtagac agggtagtga actacatgaa attattgata aatcaagaaa ggaaggagat 840
actgaggcat ggcaattccc agtaatgta gaaccgatgc cacctggaga aggagcccaa 900
gagggagagc ctcccacagt tgaggccaga tacaagtctt tttcaataaa aatgctaaaa 960
gatatgaaag aaggagtaa acagtatgga cccaactccc cttatatgag gacattatta 1020
gattccattg ctcatggaca tagactcatt ccttatgatt gggagattct ggcaaaatcg 1080
tctctctcac cctctcaatt tttacaattt aagacttggg ggattgatgg ggtacaagaa 1140
caggtccaaa gaaatagggc tgccaatcct ccagttaaca tagatgcaga tcaactatta 1200
ggaataggtc aaaattggag tactattagt caacaagcat taatgcaaaa tgaggccatt 1260
gagcaagtta gagctatctg ccttagagcc tgggaaaaaa tccaagacc aggaagtacc 1320
tgcccctcat ttaatacagt aagacaaagt tcaaaagagc cctatcctga ttttgtggca 1380
aggctccaag atgttgctca aaagtcaatt gccgatgaaa aagcccgtaa ggtcatagtg 1440
gagttgatgg catatgaaaa cgccaatcct gagtgtcaat cagccattaa gccattaaaa 1500
ggaaagggtc ctgcaggatc agatgtaatc tcagaatatg taaaagcctg tgatggaatc 1560
ggaggagcta tgcataaagc tatgcttatg gctcaagcaa taacaggagt tgtttttagga 1620
ggacaagtta gaacatttgg aggaaaatgt tacaattgtg gtcaaactcg tcaactaaaa 1680
aagaattgcc cagtcttaa caaacagaat ataactatc aagcaactac aacaggtaga 1740
gagccacctg acttatgtcc aagatgtaaa aaaggaaaac attgggctag tcaatgtcgt 1800
tctaaatttg ataaaaatgg gcaaccattg tcgggaaacg agcaaagggg ccagcctcag 1860
gccccacaac aaactggggc attcccaatt cagccatttg ttctcaggg ttttcagggg 1920
caacaacccc cactgtcca agtgtttcag ggaataagcc agttaccaca atacaacaat 1980
tgtccccac cacaagcggc agtgcagcag tag 2013

```

<210> SEQ ID NO 5

<211> LENGTH: 1224

<212> TYPE: DNA

<213> ORGANISM: Human endogenous retrovirus

<400> SEQUENCE: 5

```

caagcggcag tgcagcagta gatttatgta ctatacaagc agtctctctg cttccagggg 60
agccccaca aaaaatcccc acaggggtat atggcccact gcctgagagg actgtaggac 120
taatcttggg aagatcaagt ctaaactctaa aaggagtcca aattcactact ggtgtggttg 180

```

-continued

```

attcagacta taaaggcga attcagttgg ttattagctc ttcaattcct tggagtgcc 240
gtccaggaga caggattgct gaattattac tcctgccata tattaagggt ggaaatagt 300
aaataaaaag aacaggaggg tttggaagca ctgatccgac aggaaaggct gcatattggg 360
caagtcaggt ctcagagaac agacctgtgt gtaaggccat tattcaagga aaacagtttg 420
aagggttggt agacactgga gcagatgtct ctatcattgc tttaaactcg tggccaaaa 480
attggcctaa ccaaaggct gttacaggac ttgtcggcat aggcacagcc tcagaagtgt 540
atcaaagtac ggagatttta cattgcttag ggccagataa tcaagaaagt actgttcagc 600
caatgattac ttcaattcct cttaatctgt ggggtcgaga tttattaca caatggggtg 660
cggaaatcac catgcccgct ccatcatata gcccacgag tcaaaaaatc atgaccaaga 720
tgggatatat accaggaaag ggactagga aaaatgaaga tggcattaa attccagttg 780
aggctaaaat aatcaagaa agagaaggaa tagggtatcc ttttagggg cggccactgt 840
agagcctcct aaaccctac cattaacttg gaaaacagaa aaaccggtgt gggtaaatca 900
gtggccgcta ccaaaacaaa aactggaggc ttacattta ttagcgaatg aacagttaga 960
aaagggtcat attgagcctt cattctcacc ttggaattct cctgtgtttg taattcagaa 1020
gaaatcaggc aatggcgta tgtaactga cttaagggcc gtaaacgccg taattcaacc 1080
catggggcct ctccaacctg ggttgccctc tctggccatg atcccaaaag actggccttt 1140
aattataatt gatctaaagg attgcttttt taccatcct ctggcggagc aggattgca 1200
aaaatttgcc ttactatac cagc 1224

```

```

<210> SEQ ID NO 6
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Artifical primer

```

```

<400> SEQUENCE: 6

```

```

ccactgtaga gcctcctaaa ccc 23

```

```

<210> SEQ ID NO 7
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic primer

```

```

<400> SEQUENCE: 7

```

```

gctggtatag taaaggcaaa tttttc 26

```

```

<210> SEQ ID NO 8
<211> LENGTH: 250
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic primer

```

```

<400> SEQUENCE: 8

```

```

ccactgtaga gcctcctaaa cccataccat taacttgga aacagaaaa ccggtgtggg 60
taaactcagtg gccgctacca aaacaaaaac tggaggcttt acatttatta gcaaatgaac 120
agttagaaaa gggctcatatt gagccttcgt tctcaccttg gaattctcct gtgtttgtaa 180
ttcagaagaa atcaggcaaa tggcatatgt taactgactt aaaggccgta aacgccgtaa 240
ttcaaccat 250

```


-continued

<210> SEQ ID NO 9
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 9

Leu Met Gln Asn Glu Ala Ile Glu Gln Val Arg Ala Ile Cys Leu
 1 5 10 15

<210> SEQ ID NO 10
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 10

Ile Pro Tyr Asp Trp Glu Ile Leu Ala Lys Ser Ser Leu Ser Pro
 1 5 10 15

<210> SEQ ID NO 11
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 11

Ala Asp Gln Leu Leu Gly Ile Gly Gln Asn Trp Ser Thr Ile Ser
 1 5 10 15

<210> SEQ ID NO 12
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 12

Thr Ile Ser Gln Gln Ala Leu Met Gln Asn Glu Ala Ile Glu Gln
 1 5 10 15

<210> SEQ ID NO 13
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 13

Glu Lys Ala Arg Lys Val Ile Val Glu Leu Met Ala Tyr Glu Asn
 1 5 10 15

<210> SEQ ID NO 14
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 14

Met Ala Tyr Glu Asn Ala Asn Pro Glu Cys Gln Ser Ala Ile Lys
 1 5 10 15

<210> SEQ ID NO 15

-continued

<211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 15

Pro Val Leu Asn Lys Gln Asn Ile Thr Ile Gln Ala Thr Thr Thr
 1 5 10 15

<210> SEQ ID NO 16
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 16

Arg Ser Lys Phe Asp Lys Asn Gly Gln Pro Leu Ser Gly Asn Glu
 1 5 10 15

<210> SEQ ID NO 17
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 17

Leu Ser Gly Asn Glu Gln Arg Gly Gln Pro Gln Ala Pro Gln Gln
 1 5 10 15

<210> SEQ ID NO 18
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 18

Gln Pro Pro Leu Ser Gln Val Phe Gln Gly Ile Ser Gln Leu Pro
 1 5 10 15

<210> SEQ ID NO 19
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 19

Glu Ile Ile Asp Lys Ser Arg Lys Glu Gly Asp Thr Glu Ala Trp
 1 5 10 15

<210> SEQ ID NO 20
 <211> LENGTH: 9
 <212> TYPE: PRT
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 20

Val Ser Thr Lys Asn Leu Ile Lys Leu
 1 5

<210> SEQ ID NO 21
 <211> LENGTH: 9
 <212> TYPE: PRT

-continued

<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 21

Gly Ile Gly Gln Asn Trp Ser Thr Ile
1 5

<210> SEQ ID NO 22
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 22

Gln Tyr Gly Pro Asn Ser Pro Tyr Met
1 5

<210> SEQ ID NO 23
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 23

Cys Pro Val Leu Asn Lys Gln Asn Ile
1 5

<210> SEQ ID NO 24
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 24

Leu Thr Val Trp Asn Asp Trp Ala Ile
1 5

<210> SEQ ID NO 25
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 25

Lys Phe Asp Lys Asn Gly Gln Pro Leu
1 5

<210> SEQ ID NO 26
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 26

Gly Lys Cys Tyr Asn Cys Gly Gln Ile
1 5

<210> SEQ ID NO 27
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 27

His Leu Lys Lys Asn Cys Pro Val Leu
1 5

<210> SEQ ID NO 28

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 28

Gly Arg Lys Gly Asn Ile Ile Pro Leu
1 5

<210> SEQ ID NO 29

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 29

Phe Ser Ile Lys Met Leu Lys Asp Met
1 5

<210> SEQ ID NO 30

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 30

Pro Ala Val Asp Ser Asp Leu Thr Glu Ser Leu Asp Lys His Lys
1 5 10 15

<210> SEQ ID NO 31

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 31

Trp Asn Ser Gln Ser Ser Ile Asp Gln Lys Leu Ala Asn Gln Ile
1 5 10 15

<210> SEQ ID NO 32

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 32

Val Ser Met Asp Arg Pro Trp Glu Ala Ser Pro Ser Val His Ile
1 5 10 15

<210> SEQ ID NO 33

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic peptide

-continued

<400> SEQUENCE: 33

Pro Ala Val Gln Asn Trp Leu Val Glu Val Pro Thr Val Ser Pro
 1 5 10 15

<210> SEQ ID NO 34

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 34

Leu Arg Pro Arg Val Asn Tyr Leu Gln Asp Phe Ser Tyr Gln Arg
 1 5 10 15

<210> SEQ ID NO 35

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 35

Asn Thr Glu Val Leu Val Trp Glu Glu Cys Val Ala Asn Ser Ala
 1 5 10 15

<210> SEQ ID NO 36

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 36

Ser Ala Val Ile Leu Gln Asn Asn Glu Phe Gly Thr Ile Ile Asp
 1 5 10 15

<210> SEQ ID NO 37

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 37

Gln Phe Tyr His Asn Cys Ser Gly Gln Thr Gln Ser Cys Pro Ser
 1 5 10 15

<210> SEQ ID NO 38

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 38

Asn Arg Ser Lys Arg Phe Ile Phe Thr Leu Ile Ala Val Ile Met
 1 5 10 15

<210> SEQ ID NO 39

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 39

-continued

Pro Tyr Met Leu Val Val Gly Asn Ile
1 5

<210> SEQ ID NO 40
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 40

Ile Phe Lys Ala Ser Lys Ala His Leu
1 5

<210> SEQ ID NO 41
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 41

Lys Thr Ile Gly Ser Thr Thr Ile Ile
1 5

<210> SEQ ID NO 42
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 42

Gly Tyr His Tyr Pro Pro Ile Cys Leu
1 5

<210> SEQ ID NO 43
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 43

Ser Tyr Gln Arg Ser Leu Lys Phe Arg
1 5

<210> SEQ ID NO 44
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 44

Lys Gly Lys Pro Cys Pro Lys Glu Ile
1 5

<210> SEQ ID NO 45
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 45

Val Glu Val Pro Thr Val Ser Pro Ile
1 5

-continued

<210> SEQ ID NO 46
 <211> LENGTH: 9
 <212> TYPE: PRT
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 46

Ser Leu Arg Pro Arg Val Asn Tyr Leu
 1 5

<210> SEQ ID NO 47
 <211> LENGTH: 9
 <212> TYPE: PRT
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 47

Thr Phe Asn Trp Gln His Arg Ile Leu
 1 5

<210> SEQ ID NO 48
 <211> LENGTH: 170
 <212> TYPE: DNA
 <213> ORGANISM: Human endogenous retrovirus

<400> SEQUENCE: 48

cacacaggaa acagctatga ccatgattac gccaaagctca gaattaaccc tactaaagg 60
 gactagtctc gcaggtttaa acgaattcgc ccttaagggc gaattcgcgg ccgctaaatt 120
 caattcgcgc tatagtgagt cgtattacaa ttcactggcc gtcgttttac 170

<210> SEQ ID NO 49
 <211> LENGTH: 170
 <212> TYPE: DNA
 <213> ORGANISM: Human endogenous retrovirus

<400> SEQUENCE: 49

gtgtgtcctt tgctgatact ggtactaatg cggttcgagt ctttaattggg agtgatttcc 60
 ctgatcagga cgtccaaatt tgcttaagcg ggaattcccg ctttaagcgcc ggcgatttaa 120
 gttaagcggg atatcactca gcataatggt aagtgaccgg cagcaaaatg 170

<210> SEQ ID NO 50
 <211> LENGTH: 156
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic primer

<400> SEQUENCE: 50

ttaaacgaat tcgcccttgc tagggtgata atggggcaaa ctaaagtaa aattaaagt 60
 aatatgcct cttatctcaa gccagttacc acaatacaac aattgtcccc caccacaagc 120
 ggcagtgcag cagtagaagg gcgaatcgcg gccgct 156

<210> SEQ ID NO 51
 <211> LENGTH: 156
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic primer

<400> SEQUENCE: 51

-continued

```

ttaaacgaat tcgcccttca agcggcagtg cagcagtaga tttatgtact atacaagcag    60
tctctctgct tccaggggtt tttaccatcc ctctggcgga gcaggattgc gaaaaatttg    120
cctttactat acaagcaagg gcgaatcgcg gccgct                                156

```

```

<210> SEQ ID NO 52
<211> LENGTH: 156
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic primer

```

```

<400> SEQUENCE: 52

```

```

ttaaacgaat tcgcccttga aaaatttgcc ttactatac cagccataaa taataaagaa    60
ccagccacca ggtttcagct tctgtttgg atacccta gacatttgaa gttctacaat    120
gaacccatca gagagcaagg gcgaatcgcg gccgct                                156

```

```

<210> SEQ ID NO 53
<211> LENGTH: 156
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic primer
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (70)..(70)
<223> OTHER INFORMATION: n is a, c, g, or t

```

```

<400> SEQUENCE: 53

```

```

ttaaacgaat tcgcccttct acatgaaccc atcagagatg caaagaaaag cacctccgcg    60
gagacggagn acaccgcaca agagagatca gattgtcact gtgtctgtgt agaaagaagt    120
agacatagga gactccaagg gcgaatcgcg gccgct                                156

```

```

<210> SEQ ID NO 54
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic primer

```

```

<400> SEQUENCE: 54

```

```

cacaggtcaa accgcctagg aatg                                            24

```

```

<210> SEQ ID NO 55
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic primer

```

```

<400> SEQUENCE: 55

```

```

tctgtctcaa cttcctgtcg ag                                              22

```

```

<210> SEQ ID NO 56
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic primer

```

```

<400> SEQUENCE: 56

```

```

tcttttagcga gacgctacca tggcta                                          26

```


-continued

<210> SEQ ID NO 57
 <211> LENGTH: 27
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic primer
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (25)..(25)
 <223> OTHER INFORMATION: n = t and/or c

<400> SEQUENCE: 57

cattccttgt ggtaaaactt tccantg 27

<210> SEQ ID NO 58
 <211> LENGTH: 25
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic primer
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (23)..(23)
 <223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 58

ccccttgga tactcctggt ttntg 25

<210> SEQ ID NO 59
 <211> LENGTH: 81
 <212> TYPE: PRT
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 59

Ile	Lys	Lys	Lys	Ser	Gly	Lys	Trp	Arg	Met	Leu	Thr	Asp	Leu	Arg	Ala
1				5					10					15	
Ile	Asn	Ser	Val	Ile	Gln	Pro	Met	Gly	Ala	Leu	Gln	Pro	Gly	Leu	Pro
			20					25					30		
Ser	Pro	Ala	Ile	Ile	Pro	Lys	Asn	Trp	Pro	Leu	Val	Val	Ile	Asp	Leu
		35					40					45			
Lys	Asp	Ser	Phe	Phe	Thr	Ile	Pro	Leu	Ala	Asp	Gln	Asp	Cys	Glu	Trp
	50				55						60				
Phe	Ala	Phe	Ile	Ile	Pro	Ala	Val	Asn	Asn	Leu	Gln	Pro	Ala	Lys	His
65				70						75				80	
Phe															

The invention claimed is:

1. An isolated polynucleotide molecule comprising a nucleotide sequence of an infectious human endogenous retrovirus, which sequence is or is complementary to a sequence which:

- (a) has at least 99% identity to the full length of SEQ ID NO:1;
- (b) has 100% identity to a fragment of SEQ ID NO:1, the fragment comprising at least 15 contiguous nucleotides of SEQ ID NO:1 and including at least one of nucleotides 416, 602, 630, 639, 654, 738, 799, 802, 866, 945, 953, 972, 1149, 1348, 1413, 1642, 1653, 1668, 1701, 1989, 2068, 2087, 2090, 2097, 2100, 2124, 2163, 2198, 2238, 2253, 2273, 2305, 2313, 2330, 2461, 2808, 2815, 2816, 2878, 2938, 2974, 3052, 3091, 3105, 3124, 3178, 3363, 5402, 5719, 6456, 6458, 6464, 6802, 7146, 7262, 7340, 7347, 7388, or 7436 of SEQ ID NO:1; and/or

50

(c) comprises the sequence inserted into a vector pCR4-Topo and deposited as any of "MERV-env", "MERV-gag", "MERV-prt" and "MERV-pol" at the DSMZ on 26 Sep. 2001.

55

2. The polynucleotide molecule of claim 1, comprising the sequence of SEQ ID NO:1.

3. The polynucleotide molecule of claim 1, wherein the fragment of SEQ ID NO:1 comprises a sequence identical to the full-length of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5.

60

4. The polynucleotide molecule of claim 1, further defined as encoding an env protein of an infectious human endogenous retrovirus, said polynucleotide molecule comprising a sequence:

65

- (a) with at least 99.5% identity to the full length of the sequence of SEQ ID NO:2;
- (b) which is complementary to the full length of the nucleotide sequence of said SEQ ID NO:2; and/or

59

(c) comprises the sequence inserted into a vector pCR4-Topo and deposited as "MERV-env".

5. The polynucleotide molecule of claim 1, further defined as encoding a gag protein of an infectious human endogenous retrovirus, said polynucleotide molecule comprising a

(a) with at least 99.5% identity to the full length of the sequence of SEQ ID NO:4;

(b) which is complementary to the full length of the nucleotide sequence of said SEQ ID NO:4; and/or

(c) comprises the sequence inserted into a vector pCR4-Topo and deposited as "MERV-gag".

6. The polynucleotide molecule of claim 1, further defined as encoding a pro protein of an infectious human endogenous retrovirus, said polynucleotide molecule comprising a

(a) with at least 98% identity to the full length of the sequence of SEQ ID NO:5;

(b) which is complementary to the full length of the nucleotide sequence of said SEQ ID NO:5; and/or

(c) comprises the sequence inserted into a vector pCR4-Topo and deposited as "MERV-prt".

7. The polynucleotide molecule of claim 1, further defined as encoding a pol protein of an infectious human endogenous retrovirus, said polynucleotide molecule comprising a sequence:

60

(a) with at least 99% identity to the full length of the sequence of SEQ ID NO:3;

(b) which is complementary to the full length of the nucleotide sequence of said SEQ ID NO:3; and/or

(c) comprises the sequence inserted into a vector pCR4-Topo and deposited as "MERV-pol".

8. The polynucleotide molecule of claim 1, further comprising a detectable label.

9. The polynucleotide molecule of claim 1, further defined as a primer adapted to specifically hybridize to a second polynucleotide molecule of claim 1 in an amplification reaction.

10. The polynucleotide molecule of claim 1, wherein the polynucleotide molecule is comprised in a biologically functional vector.

11. The polynucleotide molecule of claim 10, wherein the biologically functional vector is in inverse orientation with respect to the promoter.

12. The polynucleotide molecule of claim 1, wherein the polynucleotide molecule is comprised in a recombinant host cell.

13. The polynucleotide molecule of claim 12, wherein the host cell is a mammalian cell.

* * * * *